# Clinical trial results:
# An Open-label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-cell Malignancies

## Summary

| | |
|---|---|
| EudraCT number | 2009-016378-34 |
| Trial protocol | BE FR |
| Global end of trial date | 21 March 2019 |

### Results information

| | |
|---|---|
| Result version number | v2 (current) |
| This version publication date | 20 June 2020 |
| First version publication date | 05 April 2020 |
| Version creation reason | |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | MI-CP204 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00983619 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | MedImmune, LLC |
| Sponsor organisation address | One MedImmune Way, Gaithersburg, United States, 20878 |
| Public contact | Shahram Rahimian, MedImmune, LLC, +1 800-236-9933, information.center@astrazeneca.com |
| Scientific contact | Shahram Rahimian, MedImmune, LLC, +1 800-236-9933, information.center@astrazeneca.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 12 April 2019 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 21 March 2019 |
| Global end of trial reached? | Yes |
| Global end of trial date | 21 March 2019 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the safety and tolerability, describe any dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or optimum biological dose (OBD) or highest protocol-defined doses (in the absence of exceeding the MTD) for MEDI-551 as monotherapy and in combination with rituximab in participants with relapsed or refractory advanced B-cell malignancies (chronic lymphocytic leukemia [CLL], including small lymphocytic lymphoma [SLL], diffuse large B-cell lymphoma [DLBCL], and follicular lymphoma [FL]).

Protection of trial subjects:

The conduct of this clinical study met all local and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonization guideline: Good Clinical Practice, and applicable regulatory requirements. Participants signed an informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 16 April 2010 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety, Efficacy |
| Long term follow-up duration | 6 Years |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | United States: 115 |
| Country: Number of subjects enrolled | Canada: 1 |
| Country: Number of subjects enrolled | Belgium: 11 |
| Country: Number of subjects enrolled | Italy: 5 |
| Country: Number of subjects enrolled | Spain: 4 |
| Worldwide total number of subjects | 136 |
| EEA total number of subjects | 20 |

Notes:

| Subjects enrolled per age group | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 54 |
| From 65 to 84 years | 76 |
| 85 years and over | 6 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 137 participants were screened, out of which 1 participant never received the study treatment. A total of 136 participants received study treatment.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Part A-MEDI-551 0.5 mg/kg |

Arm description:

Participants received intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 0.5 mg/kg administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part A-MEDI-551 1 mg/kg |

Arm description:

Participants received IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 1 mg/kg administered IV once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part A-MEDI-551 2 mg/kg |

Arm description:

Participants received IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 2 mg/kg administered IV on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part A-MEDI-551 4 mg/kg |

Arm description:

Participants received IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 4 mg/kg administered IV on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part A-MEDI-551 8 mg/kg |

Arm description:

Participants received IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 8 mg/kg administered IV on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part A-MEDI-551 12 mg/kg |

Arm description:

Participants received IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 12 mg/kg administered IV on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part B-MEDI-551 6 mg/kg |

Arm description:

Participants received IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 6 mg/kg administered IV weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part B-MEDI-551 12 mg/kg |

Arm description:

Participants received IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 12 mg/kg administered IV weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part B-MEDI-551 24 mg/kg |

Arm description:

Participants received IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 24 mg/kg administered IV weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| **Arm title** | Part C-MEDI-551 8 mg/kg + rituximab |

Arm description:

Participants received IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdrew consent.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | Rituximab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Rituximab 375 mg/m^2 administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws consent.

| | |
|---|---|
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 8 mg/kg administered IV on Days 2 and 8 during Cycle 1 and thereafter on Day 1 from Cycle 2 of each 28-day cycle until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws consent.

| | |
|---|---|
| **Arm title** | Part C-MEDI-551 12 mg/kg + rituximab |

Arm description:

Participants received IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdrew consent.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 12 mg/kg administered IV on Days 2 and 8 during Cycle 1 and thereafter on Day 1 from Cycle 2 of each 28-day cycle until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws.

| | |
|---|---|
| Investigational medicinal product name | Rituximab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Rituximab 375 mg/m^2 administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws consent.

| | |
|---|---|
| **Arm title** | Part D-MEDI-551 12 mg/kg |

Arm description:

Participants received IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached CR or withdrew consent.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI-551 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

MEDI-551 12 mg/kg administered IV on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment was continued until the participants experiences unacceptable toxicity, disease progression, reached CR or consent withdrawal.

| **Number of subjects in period 1** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg |
|---|---|---|---|
| Started | 3 | 4 | 3 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 4 | 3 |
| Adverse event, serious fatal | - | 2 | 2 |
| Consent withdrawn by subject | 2 | 1 | 1 |
| Not specified | 1 | - | - |
| Lost to follow-up | - | 1 | - |

| **Number of subjects in period 1** | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|
| Started | 6 | 3 | 76 |
| Completed | 1 | 0 | 9 |
| Not completed | 5 | 3 | 67 |
| Adverse event, serious fatal | 1 | 2 | 30 |
| Consent withdrawn by subject | 3 | 1 | 23 |
| Not specified | 1 | - | 12 |
| Lost to follow-up | - | - | 2 |

| **Number of subjects in period 1** | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg |
|---|---|---|---|
| Started | 3 | 3 | 1 |
| Completed | 0 | 1 | 0 |
| Not completed | 3 | 2 | 1 |
| Adverse event, serious fatal | 1 | - | 1 |
| Consent withdrawn by subject | - | - | - |
| Not specified | 2 | 2 | - |
| Lost to follow-up | - | - | - |

| **Number of subjects in period 1** | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|
| Started | 3 | 17 | 14 |
| Completed | 0 | 6 | 3 |
| Not completed | 3 | 11 | 11 |
| Adverse event, serious fatal | 2 | 9 | 8 |
| Consent withdrawn by subject | - | 1 | 1 |
| Not specified | 1 | 1 | - |

| | | | |
|---|---|---|---|
| Lost to follow-up | - | - | 2 |

### Reporting groups

| Reporting group title | Part A-MEDI-551 0.5 mg/kg |
|---|---|

Reporting group description:

Participants received intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part A-MEDI-551 1 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part A-MEDI-551 2 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part A-MEDI-551 4 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part A-MEDI-551 8 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part A-MEDI-551 12 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part B-MEDI-551 6 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part B-MEDI-551 12 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part B-MEDI-551 24 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdrew consent.

| Reporting group title | Part C-MEDI-551 12 mg/kg + rituximab |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdrew consent.

| Reporting group title | Part D-MEDI-551 12 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached CR or withdrew consent.

| **Reporting group values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg |
|---|---|---|---|
| Number of subjects | 3 | 4 | 3 |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 1 | 1 | 1 |
| From 65-84 years | 1 | 2 | 2 |
| 85 years and over | 1 | 1 | 0 |
| Age Continuous | | | |
| Here, the arbitrary number "999" signifies standard deviation not reported as only one participant was evaluable for the specified arm. | | | |
| Units: years | | | |
| arithmetic mean | 66.0 | 69.5 | 64.7 |
| standard deviation | ± 19.5 | ± 12.5 | ± 18.3 |
| Sex: Female, Male<br>Units: | | | |
| Male | 1 | 4 | 2 |
| Female | 2 | 0 | 1 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 |
| White | 3 | 3 | 3 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 4 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|
| Number of subjects | 6 | 3 | 76 |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 4 | 2 | 35 |
| From 65-84 years | 2 | 1 | 39 |
| 85 years and over | 0 | 0 | 2 |
| Age Continuous | | | |
| Here, the arbitrary number "999" signifies standard deviation not reported as only one participant was evaluable for the specified arm. | | | |
| Units: years | | | |
| arithmetic mean | 63.8 | 60.0 | 64.4 |
| standard deviation | ± 12.7 | ± 12.1 | ± 11.2 |
| Sex: Female, Male<br>Units: | | | |
| Male | 4 | 2 | 46 |
| Female | 2 | 1 | 30 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 5 |
| White | 5 | 3 | 68 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 3 |
| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 6 |
| Not Hispanic or Latino | 6 | 3 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg |
|---|---|---|---|
| Number of subjects | 3 | 3 | 1 |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 2 | 0 | 0 |
| From 65-84 years | 1 | 3 | 1 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| Here, the arbitrary number "999" signifies standard deviation not reported as only one participant was evaluable for the specified arm. | | | |
| Units: years | | | |
| arithmetic mean | 61.3 | 70.0 | 78.0 |
| standard deviation | ± 20.8 | ± 7.0 | ± 999 |
| Sex: Female, Male | | | |
| Units: | | | |
| Male | 2 | 2 | 0 |
| Female | 1 | 1 | 1 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 |
| White | 3 | 2 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 3 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |

| **Reporting group values** | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|
| Number of subjects | 3 | 17 | 14 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 1 | 3 | 4 |
| From 65-84 years | 2 | 12 | 10 |
| 85 years and over | 0 | 2 | 0 |
| Age Continuous | | | |
| Here, the arbitrary number "999" signifies standard deviation not reported as only one participant was evaluable for the specified arm. | | | |
| Units: years | | | |
| arithmetic mean | 68.0 | 69.4 | 67.9 |
| standard deviation | ± 11.8 | ± 10.8 | ± 11.0 |

| | | | |
|---|---|---|---|
| Sex: Female, Male<br>Units: | | | |
| Male | 2 | 7 | 9 |
| Female | 1 | 10 | 5 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 2 | 15 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 |
| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 17 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 |

| **Reporting group values** | Total | | |
|---|---|---|---|
| Number of subjects | 136 | | |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 54 | | |
| From 65-84 years | 76 | | |
| 85 years and over | 6 | | |
| Age Continuous | | | |
| Here, the arbitrary number "999" signifies standard deviation not reported as only one participant was evaluable for the specified arm. | | | |
| Units: years<br>arithmetic mean<br>standard deviation | -<br>- | | |
| Sex: Female, Male<br>Units: | | | |
| Male | 81 | | |
| Female | 55 | | |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | |
| Asian | 1 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 8 | | |
| White | 122 | | |

| | | | |
|---|---|---|---|
| More than one race | 0 | | |
| Unknown or Not Reported | 5 | | |
| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
| Hispanic or Latino | 6 | | |
| Not Hispanic or Latino | 130 | | |
| Unknown or Not Reported | 0 | | |

### End points reporting groups

| Reporting group title | Part A-MEDI-551 0.5 mg/kg |
|---|---|
| Reporting group description: | |
| Participants received intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part A-MEDI-551 1 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part A-MEDI-551 2 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part A-MEDI-551 4 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part A-MEDI-551 8 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part A-MEDI-551 12 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part B-MEDI-551 6 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part B-MEDI-551 12 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part B-MEDI-551 24 mg/kg |
| Reporting group description: | |
| Participants received IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed. | |
| Reporting group title | Part C-MEDI-551 8 mg/kg + rituximab |
| Reporting group description: | |
| Participants received IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdrew consent. | |
| Reporting group title | Part C-MEDI-551 12 mg/kg + rituximab |

Reporting group description:

Participants received IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdrew consent.

| Reporting group title | Part D-MEDI-551 12 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached CR or withdrew consent.

| Subject analysis set title | Part A-MEDI-551 |
|---|---|
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received IV infusion of MEDI 551 0.5 or 1 mg/kg (both, once every week in 4-week cycles), or 2, or 4, or 8, or 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Subject analysis set title | Part B-MEDI-551 |
|---|---|
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received IV infusion of MEDI- 551 6 or 12 mg/kg weekly for 4 weeks during Cycle 1 (both from Days 1, 8, 15, and 22) or 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Subject analysis set title | Part C-MEDI-551 + Rituximab |
|---|---|
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received IV infusion of MEDI- 551 8 or 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 or 12 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws consent.

| Subject analysis set title | Part A-MEDI-551 12 mg/kg (expansion) |
|---|---|
| Subject analysis set type | Per protocol |

Subject analysis set description:

Participants received IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

## Primary: Optimal Biologic Dose of MEDI-551 for Part A

| End point title | Optimal Biologic Dose of MEDI-551 for Part A[1] |
|---|---|

End point description:

Optimal biologic dose (OBD) was defined as the dose lower than the maximum tolerated dose (MTD), used for dose expansion. The MTD is defined as the highest dose at which less than equal to (<=) 1 out of 6 participants experience a dose limiting toxicities (DLT) from the time of first administration of MEDI-551 through the first 28-day cycle. The DLT evaluable population was analysed for this endpoint, which included all participants in the dose-escalation phase who received at least 1 full cycle of MEDI-551 and completed safety follow-up through the DLT evaluable period (from the time of first administration of MEDI-551 through the first 28-day of cycle 1).

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 to Day 28 of Cycle 1

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

| End point values | Part A-MEDI-551 | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 95 | | | |
| Units: mg/Kg | 12 | | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Highest protocol-defined dose for Part B

| End point title | Highest protocol-defined dose for Part B[2] |
|---|---|

End point description:

Highest protocol-defined dose is dose of MEDI-551 in the absence of exceeding the MTD in participants with relapsed or rituximab-refractory chronic lymphocytic leukemia (defined as those with less than a partial response (PR) or progression within 6 months after completing therapy with rituximab). The MTD is defined as the highest dose at which <= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 to Day 28 of Cycle 1

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

| End point values | Part B-MEDI-551 | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 7 | | | |
| Units: mg/Kg | 24 | | | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part A, Part B, and Part C

| End point title | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part A, Part B, and Part C[3][4] |
|---|---|

End point description:

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Participants | | | | |
| TEAEs | 3 | 4 | 3 | 6 |
| TESAEs | 1 | 1 | 2 | 1 |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 76 | 3 | 3 |
| Units: Participants | | | | |
| TEAEs | 3 | 76 | 3 | 3 |
| TESAEs | 1 | 23 | 1 | 2 |

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1 | 3 | 17 | |
| Units: Participants | | | | |
| TEAEs | 1 | 3 | 17 | |
| TESAEs | 1 | 1 | 9 | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Highest protocol-defined dose for Part C

| End point title | Highest protocol-defined dose for Part C[5] |
|---|---|

End point description:

Highest protocol-defined dose is the dose of MEDI-551 in combination with rituximab at the MTD or the highest protocol-defined dose in the absence of exceeding the MTD in participants with aggressive lymphomas. The MTD is defined as the highest dose at which <= 1 out of 6 participants experience a

DLT from the time of first administration of MEDI-551 through the first 28-day cycle.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 to Day 28 of Cycle 1

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

| **End point values** | Part C-MEDI-551 + Rituximab | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 20 | | | |
| Units: mg/kg | 12 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C

| End point title | Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C[6][7] |
|---|---|

End point description:

A dose limiting toxicities (DLT) for arm A, B, and C was defined as MEDI-551 (or rituximab for Arm C) treatment-related AE of any toxicity grade that led to an inability to receive a full cycle of MEDI-551 (or rituximab for Arm C) or any Grade 3 or higher toxicity (except Grade 3 fever, transient Grade 3 rigors or chills, Grade 3 tumor lysis syndrome, any Grade 3 or 4 electrolyte alteration, any Grade 3 liver function test elevation,>= Grade 3 or 4 lymphopenia or leukopenia, <= Grade 4 neutropenia, <= Grade 4 thrombocytopenia, <= Grade 4 anemia, and Grade 3 infusion-related reaction and infusion reaction), during DLT evaluable period.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 to Day 28 of Cycle 1

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Participants | 0 | 0 | 0 | 0 |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 76 | 3 | 3 |
| Units: Participants | 0 | 1 | 0 | 0 |

| End point values | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1 | 3 | 17 | |
| Units: Participants | 0 | 0 | 0 | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part A, Part B, and Part C

| End point title | Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part A, Part B, and Part C[8][9] |
|---|---|

End point description:

Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Participants | | | | |
| Anemia | 0 | 2 | 0 | 0 |
| Blood fibrinogen decreased | 0 | 1 | 0 | 0 |
| Blood fibrinogen increased | 0 | 1 | 0 | 0 |
| Febrile neutropenia | 0 | 0 | 0 | 0 |
| Hematocrit decreased | 0 | 1 | 0 | 0 |
| Hemoglobin increased | 0 | 0 | 0 | 0 |
| Leukopenia | 0 | 0 | 0 | 0 |

| | | | | |
|---|---|---|---|---|
| Lymphocyte count decreased | 0 | 1 | 0 | 0 |
| Lymphopenia | 0 | 0 | 0 | 0 |
| Myelocytosis | 0 | 0 | 0 | 0 |
| Neutropenia | 0 | 0 | 0 | 1 |
| Neutrophil count abnormal | 0 | 1 | 0 | 0 |
| Neutrophil count decreased | 1 | 1 | 0 | 1 |
| Platelet count decreased | 0 | 0 | 0 | 0 |
| Red blood cell count decreased | 0 | 1 | 0 | 0 |
| Reticulocytosis | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 0 | 1 | 0 | 3 |
| White blood cell count decreased | 0 | 0 | 0 | 1 |
| Hypergammaglobulinemia | 0 | 0 | 0 | 0 |
| Activated PTT prolonged | 0 | 0 | 0 | 0 |
| Leukocytosis | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased | 0 | 1 | 0 | 0 |
| Aspartate aminotransferase increased | 0 | 1 | 0 | 0 |
| Blood alkaline phosphatase increased | 0 | 0 | 0 | 0 |
| Blood chloride decreased | 0 | 1 | 0 | 0 |
| Blood creatinine increased | 0 | 0 | 1 | 0 |
| Blood glucose decreased | 0 | 0 | 0 | 0 |
| Blood glucose increased | 0 | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | 0 | 0 | 0 | 0 |
| Blood potassium decreased | 0 | 0 | 0 | 0 |
| Blood urea increased | 0 | 1 | 0 | 0 |
| Blood uric acid increased | 0 | 0 | 0 | 0 |
| Gamma-glutamyl transferase increased | 0 | 0 | 0 | 0 |
| Hyperbilirubinemia | 0 | 0 | 0 | 1 |
| Hypercalcemia | 0 | 0 | 0 | 0 |
| Hyperglycemia | 0 | 0 | 0 | 1 |
| Hyperkalemia | 0 | 2 | 0 | 0 |
| Hyperuricemia | 1 | 1 | 0 | 0 |
| Hypocalcemia | 0 | 2 | 0 | 0 |
| Hypoglycemia | 0 | 1 | 0 | 0 |
| Hypokalemia | 0 | 0 | 0 | 0 |
| Hypomagnesemia | 0 | 0 | 0 | 0 |
| Hyponatremia | 0 | 1 | 0 | 1 |
| Protein total decreased | 0 | 0 | 0 | 1 |
| Blood albumin decreased | 0 | 0 | 0 | 0 |
| Hypernatremia | 0 | 0 | 0 | 0 |
| Hypoalbuminemia | 0 | 0 | 0 | 0 |
| Haematuria | 0 | 0 | 0 | 0 |
| Dysuria | 0 | 0 | 0 | 0 |
| Pollakiuria | 0 | 0 | 0 | 0 |
| Hemoglobinuria | 0 | 0 | 0 | 0 |
| Hydronephrosis | 0 | 0 | 0 | 0 |
| Urinary incontinence | 0 | 0 | 0 | 0 |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|

| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
|---|---|---|---|---|
| Number of subjects analysed | 3 | 76 | 3 | 3 |
| Units: Participants | | | | |
| Anemia | 1 | 6 | 0 | 1 |
| Blood fibrinogen decreased | 0 | 0 | 0 | 1 |
| Blood fibrinogen increased | 0 | 1 | 0 | 1 |
| Febrile neutropenia | 0 | 2 | 0 | 1 |
| Hematocrit decreased | 0 | 0 | 0 | 0 |
| Hemoglobin increased | 0 | 1 | 0 | 0 |
| Leukopenia | 0 | 1 | 0 | 1 |
| Lymphocyte count decreased | 0 | 0 | 0 | 0 |
| Lymphopenia | 0 | 2 | 0 | 1 |
| Myelocytosis | 0 | 1 | 0 | 0 |
| Neutropenia | 1 | 14 | 1 | 1 |
| Neutrophil count abnormal | 0 | 0 | 0 | 0 |
| Neutrophil count decreased | 0 | 5 | 0 | 1 |
| Platelet count decreased | 0 | 2 | 0 | 1 |
| Red blood cell count decreased | 0 | 0 | 0 | 0 |
| Reticulocytosis | 0 | 1 | 0 | 0 |
| Thrombocytopenia | 0 | 6 | 0 | 1 |
| White blood cell count decreased | 1 | 3 | 0 | 2 |
| Hypergammaglobulinemia | 0 | 0 | 1 | 0 |
| Activated PTT prolonged | 0 | 0 | 0 | 0 |
| Leukocytosis | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased | 0 | 3 | 0 | 0 |
| Aspartate aminotransferase increased | 0 | 4 | 0 | 0 |
| Blood alkaline phosphatase increased | 0 | 1 | 0 | 0 |
| Blood chloride decreased | 0 | 0 | 0 | 0 |
| Blood creatinine increased | 0 | 1 | 0 | 1 |
| Blood glucose decreased | 0 | 1 | 0 | 0 |
| Blood glucose increased | 0 | 1 | 0 | 0 |
| Blood lactate dehydrogenase increased | 0 | 2 | 0 | 0 |
| Blood potassium decreased | 0 | 1 | 0 | 0 |
| Blood urea increased | 0 | 0 | 0 | 0 |
| Blood uric acid increased | 0 | 1 | 0 | 0 |
| Gamma-glutamyl transferase increased | 0 | 3 | 0 | 0 |
| Hyperbilirubinemia | 0 | 0 | 0 | 0 |
| Hypercalcemia | 0 | 4 | 0 | 0 |
| Hyperglycemia | 0 | 1 | 0 | 0 |
| Hyperkalemia | 0 | 0 | 0 | 0 |
| Hyperuricemia | 0 | 2 | 0 | 0 |
| Hypocalcemia | 0 | 0 | 0 | 1 |
| Hypoglycemia | 0 | 1 | 0 | 0 |
| Hypokalemia | 0 | 1 | 0 | 1 |
| Hypomagnesemia | 0 | 2 | 0 | 1 |
| Hyponatremia | 0 | 0 | 0 | 0 |
| Protein total decreased | 0 | 0 | 0 | 1 |
| Blood albumin decreased | 0 | 0 | 0 | 1 |
| Hypernatremia | 0 | 0 | 0 | 0 |
| Hypoalbuminemia | 0 | 0 | 0 | 0 |
| Haematuria | 0 | 2 | 0 | 0 |
| Dysuria | 0 | 1 | 0 | 0 |

| | | | | |
|---|---|---|---|---|
| Pollakiuria | 0 | 2 | 0 | 0 |
| Hemoglobinuria | 0 | 2 | 0 | 0 |
| Hydronephrosis | 0 | 0 | 0 | 0 |
| Urinary incontinence | 0 | 1 | 0 | 0 |

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1 | 3 | 17 | |
| Units: Participants | | | | |
| Anemia | 1 | 0 | 4 | |
| Blood fibrinogen decreased | 0 | 0 | 0 | |
| Blood fibrinogen increased | 0 | 0 | 0 | |
| Febrile neutropenia | 0 | 0 | 1 | |
| Hematocrit decreased | 0 | 0 | 0 | |
| Hemoglobin increased | 0 | 0 | 0 | |
| Leukopenia | 0 | 0 | 0 | |
| Lymphocyte count decreased | 1 | 0 | 2 | |
| Lymphopenia | 0 | 0 | 0 | |
| Myelocytosis | 0 | 0 | 0 | |
| Neutropenia | 0 | 1 | 2 | |
| Neutrophil count abnormal | 0 | 0 | 0 | |
| Neutrophil count decreased | 1 | 0 | 2 | |
| Platelet count decreased | 1 | 0 | 1 | |
| Red blood cell count decreased | 0 | 0 | 0 | |
| Reticulocytosis | 0 | 0 | 0 | |
| Thrombocytopenia | 0 | 0 | 2 | |
| White blood cell count decreased | 1 | 0 | 2 | |
| Hypergammaglobulinemia | 0 | 0 | 0 | |
| Activated PTT prolonged | 0 | 0 | 1 | |
| Leukocytosis | 0 | 0 | 1 | |
| Alanine aminotransferase increased | 1 | 0 | 1 | |
| Aspartate aminotransferase increased | 1 | 0 | 1 | |
| Blood alkaline phosphatase increased | 1 | 0 | 2 | |
| Blood chloride decreased | 0 | 0 | 0 | |
| Blood creatinine increased | 1 | 0 | 2 | |
| Blood glucose decreased | 0 | 0 | 0 | |
| Blood glucose increased | 0 | 0 | 0 | |
| Blood lactate dehydrogenase increased | 1 | 0 | 1 | |
| Blood potassium decreased | 0 | 0 | 0 | |
| Blood urea increased | 0 | 0 | 0 | |
| Blood uric acid increased | 0 | 0 | 0 | |
| Gamma-glutamyl transferase increased | 0 | 0 | 0 | |
| Hyperbilirubinemia | 0 | 0 | 1 | |
| Hypercalcemia | 0 | 0 | 1 | |
| Hyperglycemia | 0 | 0 | 2 | |
| Hyperkalemia | 0 | 0 | 0 | |
| Hyperuricemia | 1 | 0 | 1 | |
| Hypocalcemia | 1 | 0 | 2 | |

| | | | | |
|---|---|---|---|---|
| Hypoglycemia | 0 | 0 | 1 | |
| Hypokalemia | 0 | 0 | 1 | |
| Hypomagnesemia | 0 | 0 | 1 | |
| Hyponatremia | 0 | 0 | 2 | |
| Protein total decreased | 0 | 0 | 0 | |
| Blood albumin decreased | 0 | 0 | 0 | |
| Hypernatremia | 1 | 0 | 2 | |
| Hypoalbuminemia | 1 | 0 | 2 | |
| Haematuria | 0 | 0 | 2 | |
| Dysuria | 0 | 0 | 2 | |
| Pollakiuria | 0 | 0 | 0 | |
| Hemoglobinuria | 0 | 0 | 0 | |
| Hydronephrosis | 0 | 0 | 2 | |
| Urinary incontinence | 0 | 0 | 1 | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A, Part B, and Part C

| End point title | Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A, Part B, and Part C[10][11] |
|---|---|

End point description:

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry). The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Participants | | | | |
| Bradycardia | 1 | 0 | 0 | 0 |
| Chills | 0 | 0 | 0 | 1 |
| Dyspnea | 0 | 1 | 1 | 1 |
| Hypertension | 2 | 1 | 0 | 0 |
| Hypotension | 1 | 3 | 1 | 0 |
| Orthostatic hypotension | 0 | 0 | 1 | 0 |

| | | | | |
|---|---|---|---|---|
| Palpitations | 0 | 0 | 0 | 0 |
| Pyrexia | 0 | 0 | 1 | 2 |
| Systolic hypertension | 0 | 0 | 0 | 0 |
| Tachycardia | 0 | 0 | 0 | 0 |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 76 | 3 | 3 |
| Units: Participants | | | | |
| Bradycardia | 0 | 0 | 0 | 0 |
| Chills | 0 | 5 | 0 | 1 |
| Dyspnea | 0 | 10 | 0 | 2 |
| Hypertension | 0 | 8 | 0 | 2 |
| Hypotension | 0 | 4 | 0 | 0 |
| Orthostatic hypotension | 0 | 0 | 0 | 0 |
| Palpitations | 0 | 1 | 0 | 0 |
| Pyrexia | 0 | 16 | 1 | 1 |
| Systolic hypertension | 0 | 2 | 0 | 0 |
| Tachycardia | 0 | 6 | 1 | 0 |

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1 | 3 | 17 | |
| Units: Participants | | | | |
| Bradycardia | 0 | 0 | 0 | |
| Chills | 0 | 0 | 1 | |
| Dyspnea | 1 | 0 | 4 | |
| Hypertension | 0 | 0 | 2 | |
| Hypotension | 1 | 0 | 2 | |
| Orthostatic hypotension | 0 | 0 | 0 | |
| Palpitations | 0 | 0 | 1 | |
| Pyrexia | 0 | 0 | 3 | |
| Systolic hypertension | 0 | 0 | 0 | |
| Tachycardia | 0 | 0 | 1 | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part A, Part B, and Part C

| End point title | Number of Participants With Abnormal Electrocardiograms |
|---|---|

| | |
|---|---|
| | Reported as TEAEs in Part A, Part B, and Part C[12][13] |

End point description:

Number of participants with abnormal electrocardiograms (ECGs) reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Participants | | | | |
| Sinus bradycardia | 0 | 1 | 0 | 0 |
| Atrial fibrillation | 0 | 0 | 0 | 0 |
| Mitral valve incompetence | 0 | 0 | 0 | 0 |
| Supraventricular extrasystoles | 0 | 0 | 0 | 0 |
| Tricuspid valve incompetence | 0 | 0 | 0 | 0 |
| ECG QT prolonged | 0 | 0 | 1 | 0 |
| Atrial flutter | 0 | 0 | 0 | 0 |
| Atrial tachycardia | 0 | 0 | 0 | 0 |
| supraventricular tachycardia | 0 | 0 | 0 | 0 |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 76 | 3 | 3 |
| Units: Participants | | | | |
| Sinus bradycardia | 0 | 0 | 0 | 0 |
| Atrial fibrillation | 0 | 3 | 0 | 1 |
| Mitral valve incompetence | 0 | 1 | 0 | 0 |
| Supraventricular extrasystoles | 0 | 1 | 0 | 0 |
| Tricuspid valve incompetence | 0 | 1 | 0 | 0 |
| ECG QT prolonged | 0 | 1 | 0 | 0 |
| Atrial flutter | 0 | 0 | 0 | 1 |
| Atrial tachycardia | 0 | 0 | 0 | 1 |
| supraventricular tachycardia | 0 | 0 | 0 | 1 |

| End point values | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1 | 3 | 17 | |
| Units: Participants | | | | |
| Sinus bradycardia | 0 | 0 | 0 | |
| Atrial fibrillation | 0 | 0 | 0 | |
| Mitral valve incompetence | 0 | 1 | 0 | |
| Supraventricular extrasystoles | 0 | 0 | 0 | |
| Tricuspid valve incompetence | 0 | 0 | 0 | |
| ECG QT prolonged | 0 | 0 | 1 | |
| Atrial flutter | 0 | 0 | 0 | |
| Atrial tachycardia | 0 | 0 | 0 | |
| supraventricular tachycardia | 0 | 0 | 1 | |

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants With Complete Response for Part B, Part C, and Part D

| End point title | Percentage of Participants With Complete Response for Part B, Part C, and Part D[14][15] |
|---|---|

End point description:

Complete response (CR) is defined as disappearance of all evidence of disease according to International Working Group criteria (IWG). For nodal masses; fluorodeoxyglucose (FDG)-avid or polyethylene terephthalate (PET) positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT). For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry (IHC) was negative. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (EOT) (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[16] | 3 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 33.3 (0.8 to 90.6) | 0 (0.0 to 70.8) | ( to ) | 33.3 (0.8 to 90.6) |

Notes:

[16] - No participants were analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 18.8 (4.0 to 45.6) | 0 (0.0 to 24.7) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants With Partial Response for Part B, Part C, and Part D

| End point title | Percentage of Participants With Partial Response for Part B, Part C, and Part D[17][18] |
|---|---|

End point description:

The partial response (PR) is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: >= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: >= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[19] | 3 |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 33.3 | 33.3 | | 33.3 |

Notes:

[19] - No participants were analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 25.0 | 23.1 | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Duration of Complete Response for Part B, Part C, and Part D

| End point title | Duration of Complete Response for Part B, Part C, and Part |
|---|---|

End point description:

Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. Duration of CR is calculated for participants with CR. Here, the arbitrary number "20.999" signifies that median was not estimable because insufficient number of participants had events.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1[22] | 0[23] | 0[24] | 1[25] |
| Units: Months | | | | |
| median (full range (min-max)) | 5.6 (5.6 to 5.6) | ( to ) | ( to ) | 0.3 (0.3 to 0.3) |

Notes:

[22] - An arbitrary value for median is reported as 5.6 (Median was not calculated, as < 3 participants).

[23] - No participants were analysed, as no response was observed in this specified arm.

[24] - No participants were analysed for the specified arm.

[25] - An arbitrary value for median is reported as 0.3 (Median was not calculated, as < 3 participants).

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 0[26] | | |
| Units: Months | | | | |
| median (full range (min-max)) | 20.999 (20.0 to 38.4) | ( to ) | | |

Notes:

[26] - No participants were analysed, as no response was observed in this specified arm.

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D

| End point title | Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D[27][28] |
|---|---|

End point description:

ORR is proportion of participants with CR or partial response (PR) as per IWG criteria. CR is disappearance of all evidence of disease (Nodal masses: FDG-avid/PET positive prior to therapy; mass of any size permitted if PET negative; FDG-avid or PET negative - regression to normal size on CT; spleen nodules disappeared; cleared bone marrow infiltrate on repeat biopsy; IHC was negative if unknown by morphology). PR is regression of measurable disease and no new sites as: Nodal masses: >= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes: a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site; b) FDG-avid or PET negative; regression on CT. Spleen and liver: >= 50% decrease in SPD of nodules. Bone marrow: irrelevant if positive prior to therapy. Evaluable population for efficacy is used for this endpoint.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[29] | 3 |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 66.7 (9.4 to 99.2) | 33.3 (0.8 to 90.6) | ( to ) | 66.7 (9.4 to 99.2) |

Notes:

[29] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 43.8 (19.8 to 70.1) | 23.1 (5.0 to 53.8) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Duration of Objective Response for Part B, Part C, and Part D

| End point title | Duration of Objective Response for Part B, Part C, and Part |
|---|---|

End point description:

Duration of objective response (DOR) is the first documentation of objective response to the first documented progressive disease (PD) or relapse according to IWG criteria. PD is defined as any new lesion or increase by >=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) > 1.5 cm in any axis, >= 50% increase in SPD of more than one node, or >= 50% increase in longest diameter of a previously identified node > 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: > 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR. Evaluable population for efficacy was analysed for this endpoint. The DOR were calculated for participants with objective response. Here, the arbitrary numbers "38.9999 and 1.9999" signifies that median was not estimable because insufficient number of participants had events.

| End point type | Primary |
|---|---|

End point timeframe:

Cycle 1 Day 1, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 1 | 0[32] | 2 |
| Units: Months | | | | |
| median (full range (min-max)) | 38.9999 (38.9 to 47.2) | 27.5 (27.5 to 27.5) | ( to ) | 3.7 (2.4 to 3.7) |

Notes:

[32] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 7 | 3 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 1.9999 (1.0 to 44.7) | 3.7 (1.9 to 27.2) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D

| End point title | Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D[33][34] |
|---|---|

End point description:

Disease control includes CR, PR, or stable disease (SD) for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. Nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: >= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Spleen and liver: >= 50% decrease in SPD of nodules. Bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD. Evaluable population for efficacy was analysed for this endpoint.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[35] | 3 |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 100 (29.2 to 100) | 100 (29.2 to 100) | ( to ) | 100 (29.2 to 100) |

Notes:

[35] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 6 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 68.8 (41.3 to 89.0) | 46.2 (19.2 to 74.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Duration of Disease Control for Part B, Part C, and Part D

| End point title | Duration of Disease Control for Part B, Part C, and Part D[36][37] |
|---|---|

End point description:

Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse. PD is defined as any new lesion or increase by >=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion > 1.5 cm in any axis, >= 50% increase in SPD of more than one node, or >= 50% increase in longest diameter of a previously identified node > 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: > 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control. Evaluable population for efficacy was analysed for this endpoint. Duration of disease control is calculated for the participants with objective response or stable disease response. The arbitrary number "9.9999" signifies that median was not estimable because insufficient number of participants had events.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[38] | 3 |
| Units: Months | | | | |
| median (full range (min-max)) | 9.9999 (9.7 to 50.9) | 29.8 (22.6 to 39.5) | ( to ) | 5.5 (4.2 to 5.5) |

Notes:

[38] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 6 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 14.6 (1.7 to 46.5) | 3.8 (3.5 to 29.0) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Time to Response for Part B, Part C, and Part D

| End point title | Time to Response for Part B, Part C, and Part D[39][40] |
|---|---|

End point description:

Time to response (TTR) is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. TTR were calculated for the participants with objective response.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 1 | 0[41] | 2 |
| Units: Months | | | | |
| median (full range (min-max)) | 6.5 (3.7 to 9.2) | 12.0 (12.0 to 12.0) | ( to ) | 1.8 (1.7 to 1.8) |

Notes:

[41] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 7 | 3 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 2.0 (1.7 to 17.3) | 1.8 (1.6 to 1.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Progression Free Survival for Part B, Part C, and Part D

| End point title | Progression Free Survival for Part B, Part C, and Part D[42][43] |
|---|---|

End point description:

Progression-free survival (PFS) is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy. Kaplan-Meier method was used to evaluate PFS. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. Here, the arbitrary number "9.9999" signifies that median was not estimable because insufficient number of participants had events.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[44] | 3 |
| Units: Months | | | | |
| median (full range (min-max)) | 9.9999 (9.7 to 50.9) | 29.8 (22.6 to 39.5) | ( to ) | 5.5 (4.2 to 5.5) |

Notes:

[44] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 3.5 (0.7 to 46.5) | 2.0 (0.7 to 29.0) | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Overall Survival for Part B, Part C, and Part D

| End point title | Overall Survival for Part B, Part C, and Part D[45][46] |
|---|---|

End point description:

Overall survival (OS) is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. Here, the arbitrary number "19.9999 and 37.9999" signifies that median was not estimable because insufficient number of participants had events.

| End point type | Primary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for this end point.
[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 3 | 0[47] | 3 |
| Units: Months | | | | |
| median (full range (min-max)) | 19.9999 (19.4 to 53.8) | 37.9999 (37.6 to 41.9) | ( to ) | 25.0 (18.3 to 45.4) |

Notes:

[47] - No participant was analysed for the specified arm.

| End point values | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 33.4 (0.9 to 51.3) | 17.9 (1.2 to 38.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part D

| End point title | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part D[48] |
|---|---|

End point description:

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part D-MEDI-551 12 mg/kg | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: Participants | | | | |
| TEAEs | 14 | | | |
| TESAEs | 5 | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part D

| End point title | Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part D[49] |
|---|---|

End point description:

Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part D-MEDI-551 12 mg/kg | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: Participants | | | | |
| Anemia | 2 | | | |
| Febrile neutropenia | 1 | | | |
| Lymphocyte count decreased | 3 | | | |
| Neutropenia | 1 | | | |
| Neutrophil count decreased | 4 | | | |
| Platelet count decreased | 1 | | | |
| Polycythemia | 1 | | | |
| Thrombocytopenia | 2 | | | |
| White blood cell count decreased | 3 | | | |
| Blood ALP increased | 1 | | | |
| Blood bilirubin increased | 1 | | | |
| Blood LDH increased | 1 | | | |
| Blood potassium decreased | 1 | | | |
| Hypercalcemia | 1 | | | |
| Hyperglycemia | 2 | | | |
| Hyperuricemia | 2 | | | |

| | | | | |
|---|---|---|---|---|
| Hypocalcemia | 1 | | | |
| Hypokalemia | 2 | | | |
| Pollakiuria | 1 | | | |
| Urinary incontinence | 1 | | | |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part D

| End point title | Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part D[50] |
|---|---|

End point description:

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry). The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part D-MEDI-551 12 mg/kg | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: Participants | | | | |
| Chills | 2 | | | |
| Dyspnea | 1 | | | |
| Hypertension | 1 | | | |
| Hypotension | 1 | | | |
| Palpitations | 1 | | | |
| Pyrexia | 2 | | | |
| Tachycardia | 1 | | | |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D

| End point title | Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D[51] |
|---|---|

End point description:

Number of participants with abnormal ECGs reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part D-MEDI-551 12 mg/kg | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 | | | |
| Units: Participants | | | | |
| ECG QT prolonged | 1 | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With Complete Response for Part A

| End point title | Percentage of Participants With Complete Response for Part |
|---|---|

End point description:

The CR is defined as disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 5 |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 33.3 (0.8 to 90.6) | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 20.0 (0.5 to 71.6) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 72 | | |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 0 (0.0 to 70.8) | 12.5 (5.9 to 22.4) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With Partial Response for Part A

| End point title | Percentage of Participants With Partial Response for Part A[53] |
|---|---|

End point description:

The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: >= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: >= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy. Evaluable population for efficacy included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 5 |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 33.3 | 0 | 0 | 0 |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 72 | | |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 33.3 | 15.3 | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Complete Response for Part A

| End point title | Duration of Complete Response for Part A[54] |
|---|---|

End point description:

Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. Duration of CR is calculated for participants with CR.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 0[55] | 0[56] | 1 |
| Units: Months | | | | |
| median (full range (min-max)) | 7.1 (7.1 to 7.1) | ( to ) | ( to ) | 14.9 (14.9 to 14.9) |

Notes:

[55] - No participants were analysed, as no response was observed in this specified arm.

[56] - No participants were analysed, as no response was observed in this specified arm.

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0[57] | 9 | | |
| Units: Months | | | | |
| median (full range (min-max)) | ( to ) | 14.3 (1.9 to 31.8) | | |

Notes:

[57] - No participants were analysed, as no response was observed in this specified arm.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With Objective Response Rate for Part A

| End point title | Percentage of Participants With Objective Response Rate for Part A[58] |
|---|---|

End point description:

The ORR is defined as proportion of participants with CR or PR according to IWG criteria. CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: >= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site b) FDG-avid or PET negative; regression on CT. For spleen and liver: >= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. Evaluable population for efficacy was analysed for this endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 5 |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 66.7 (9.4 to 99.2) | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 20.0 (0.5 to 71.6) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 72 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 33.3 (0.8 to 90.6) | 27.8 (17.9 to 39.6) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Objective Response for Part A

| End point title | Duration of Objective Response for Part A[59] |
|---|---|

End point description:

The DOR is the first documentation of objective response to the first documented PD or relapse

according to IWG criteria. PD is defined as any new lesion or increase by >=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) > 1.5 cm in any axis, >= 50% increase in SPD of more than one node, or >= 50% increase in longest diameter of a previously identified node > 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: > 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. The DOR were calculated for participants with objective response.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 0[60] | 0[61] | 1 |
| Units: Months | | | | |
| median (full range (min-max)) | 8.8 (7.4 to 8.8) | ( to ) | ( to ) | 15.0 (15.0 to 15.0) |

Notes:

[60] - No participants were analysed, as no response was observed in this specified arm.

[61] - No participants were analysed, as no response was observed in this specified arm.

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 20 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 3.0 (3.0 to 3.0) | 19.8 (0.0 to 41.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With Disease Control Rate for Part A

| End point title | Percentage of Participants With Disease Control Rate for Part |
|---|---|

End point description:

Disease control includes CR, PR, or SD for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG -avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: >= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site b) Variably FDG-avid or PET negative; regression on CT. For spleen and liver: >= 50% decrease in SPD of nodules. For bone marrow: irrelevant if positive prior to therapy. SD is failure to

attain CR/PR or PD. Evaluable population for efficacy was analysed for this endpoint.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 2 | 4 |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 66.7 (9.4 to 99.2) | 50.0 (6.8 to 93.2) | 66.7 (9.4 to 99.2) | 80.0 (28.4 to 99.5) |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2 | 53 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 66.7 (9.4 to 99.2) | 73.6 (61.9 to 83.3) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Disease Control for Part A

| End point title | Duration of Disease Control for Part A[63] |
|---|---|

End point description:

Duration of disease control is defined as time period from start of MEDI-551 administration to event of PD/relapse according to IWG criteria. PD is defined as new lesion or increase by >=50% of previously involved sites from nadir. Nodal masses:appearance of a new lesion >1.5 cm in any axis, >= 50% increase in SPD of more than one node, or >= 50% increase in longest diameter of a previously identified node >1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. Spleen: >50% increase from nadir in the SPD of any previous lesions. Bone marrow:New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control. Evaluable population for efficacy was analysed for this endpoint. Duration of disease control is calculated for the participants with objective response or stable disease response. Arbitrary numbers "9.9999 and 3.9999" signifies median was not estimable because insufficient number of participants had events.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 2 | 2 | 4 |
| Units: Months | | | | |
| median (full range (min-max)) | 12.6 (1.4 to 12.6) | 9.9999 (9.4 to 21.0) | 3.9999 (3.5 to 7.4) | 10.9 (3.9 to 94.9) |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2 | 53 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 6.6 (2.8 to 6.6) | 18.0 (0.9 to 49.7) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Response for Part A

| End point title | Time to Response for Part A[64] |
|---|---|

End point description:

The TTR is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. TTR were calculated for the participants with objective response.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 2 | 0[65] | 0[66] | 1 |
| Units: Months | | | | |
| median (full range (min-max)) | 3.7 (3.5 to 3.9) | ( to ) | ( to ) | 1.9 (1.9 to 1.9) |

Notes:

[65] - No participants were analysed, as no response was observed in this specified arm.

[66] - No participants were analysed, as no response was observed in this specified arm.

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1 | 20 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 3.6 (3.6 to 3.6) | 3.2 (0.3 to 22.6) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression Free Survival for Part A

| End point title | Progression Free Survival for Part A[67] |
|---|---|

End point description:

The PFS is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. Kaplan-Meier method was used to evaluate PFS. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 5 |
| Units: Months | | | | |
| median (full range (min-max)) | 12.6 (1.4 to 12.6) | 5.9 (0.6 to 21.0) | 3.5 (1.6 to 9.9) | 4.9 (1.1 to 94.9) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 72 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 6.6 (2.1 to 6.6) | 11.3 (0.0 to 49.7) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival for Part A

| End point title | Overall Survival for Part A[68] |
|---|---|

End point description:

The OS is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS. Evaluable population for efficacy was analysed for this endpoint, which included all participants who received any treatment of MEDI-551 and completed at least one post-baseline disease assessment. Here, the arbitrary number "1.9999" signifies that median was not estimable because insufficient number of participants had events.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Notes:

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 5 |
| Units: Months | | | | |
| median (full range (min-max)) | 1.9999 (1.4 to 21.5) | 44.6 (0.8 to 91.5) | 9.9 (2.8 to 9.9) | 1.9999 (1.7 to 94.9) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 72 | | |
| Units: Months | | | | |
| median (full range (min-max)) | 8.1 (2.8 to 12.5) | 45.3 (0.7 to 83.5) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Trough Serum Concentration of MEDI-551 by Treatment Cycle

| End point title | Trough Serum Concentration of MEDI-551 by Treatment Cycle |
|---|---|

End point description:

Trough serum concentration (Ctrough) is defined as lowest concentration reached by a drug before the next dose is administered. The PK population was analysed for this endpoint, which included all participants who received at least one dose of MEDI-551 and had at least one measurable serum concentration of MEDI-551. Here, the arbitrary numbers "999", "9999", "99999", and "999999" signifies that the sample was below limit of quantification, analysis is not applicable, standard deviation is not reported as only one participant was evaluable, and no participants were analysed for the specified arms respectively.

| End point type | Secondary |
|---|---|

End point timeframe:

For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1D1(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 66) | 999 (± 999) | 0.333 (± 0.665) | 999 (± 999) | 999 (± 999) |
| C1D2(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 67) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C1D8(n= 3, 4, 3,6,3,6,3,3,1,3,16,14,67) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C1D15(n= 3,4,3, 6, 3, 6,3, 3, 1,3 17,14,67) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C1D22(n= 3,4,3,6,3,6,3,3,0,3,17,14,67) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C2D1(n= 3,3,3,4,3,6,3,3,0,3,12,11,56) | 15.6 (± 0.823) | 25.9 (± 10.9) | 12.9 (± 4.55) | 59.4 (± 11.0) |
| C3D1(n= 2,3,2, 4,2,6,3,3,0,3,11,6,46) | 19.3 (± 3.33) | 26.9 (± 12.2) | 6.78 (± 2.01) | 43.0 (± 8.40) |
| C4D1(n=2,2,2,4,1,5,3,3,0,3,10,6,43) | 20.9 (± 6.69) | 36.5 (± 0.550) | 5.59 (± 0.146) | 37.9 (± 13.8) |
| C5D1(n= 2,2,0,3,1,3,3,3,0,2,7, 2, 34) | 26.6 (± 7.17) | 46.8 (± 8.03) | 999999 (± 999999) | 56.9 (± 19.6) |
| C6D1 (n= 2,2,1,1,1,3,3,3,0,1,7,2, 35) | 29.1 (± 6.17) | 29.1 (± 17.3) | 11.7 (± 99999) | 32.0 (± 99999) |
| C7D1(n= 2,2,1,1,1,3,3,3,0,1 5,1, 28) | 31.4 (± 7.08) | 25.1 (± 27.8) | 9.93 (± 99999) | 38.2 (± 99999) |
| C8D1 (n= 2,2,1,1,0,1,3,3,0,0,5,1, 27) | 27.1 (± 14.9) | 28.0 (± 1.86) | 8.80 (± 99999) | 33.3 (± 99999) |
| C9D1(n= 1,2, 1, 1, 0, 2, 3, 3, 0, 0, 5, 2, 22) | 21.6 (± 99999) | 31.6 (± 1.23) | 10.7 (± 99999) | 33.6 (± 99999) |
| C10D1(n= 1, 1, 1, 1, 0, 2, 3, 3, 0, 0, 4, 1, 23) | 17.6 (± 99999) | 25.1 (± 99999) | 10.6 (± 99999) | 32.9 (± 99999) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|

| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
|---|---|---|---|---|
| Number of subjects analysed | 3 | 6 | 3 | 3 |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1D1(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 66) | 999 (± 999) | 999 (± 999) | 999 (± 999) | 999 (± 999) |
| C1D2(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 67) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C1D8(n= 3, 4, 3,6,3,6,3,3,1,3,16,14,67) | 9999 (± 9999) | 9999 (± 9999) | 46.5 (± 20.9) | 102 (± 25.0) |
| C1D15(n= 3,4,3, 6, 3, 6,3, 3, 1,3 17,14,67) | 9999 (± 9999) | 9999 (± 9999) | 81.8 (± 38.3) | 197 (± 51.2) |
| C1D22(n= 3,4,3,6,3,6,3,3,0,3,17,14,67) | 9999 (± 9999) | 9999 (± 9999) | 116 (± 47.4) | 281 (± 29.5) |
| C2D1(n= 3,3,3,4,3,6,3,3,0,3,12,11,56) | 89.8 (± 64.9) | 166 (± 54.0) | 122 (± 37.2) | 326 (± 68.0) |
| C3D1(n= 2,3,2, 4,2,6,3,3,0,3,11,6,46) | 97.0 (± 94.5) | 149 (± 46.2) | 57.6 (± 43.1) | 187 (± 80.6) |
| C4D1(n=2,2,2,4,1,5,3,3,0,3,10,6,43) | 33.4 (± 99999) | 146 (± 55.5) | 36.0 (± 31.6) | 134 (± 67.7) |
| C5D1(n= 2,2,0,3,1,3,3,3,0,2,7, 2, 34) | 31.8 (± 99999) | 136 (± 19.3) | 35.7 (± 32.0) | 121 (± 78.1) |
| C6D1 (n= 2,2,1,1,1,3,3,3,0,1,7,2, 35) | 33.7 (± 99999) | 138 (± 27.2) | 37.3 (± 33.5) | 106 (± 54.6) |
| C7D1(n= 2,2,1,1,1,3,3,3,0,1 5,1, 28) | 27.9 (± 99999) | 144 (± 42.4) | 28.1 (± 21.2) | 95.1 (± 54.4) |
| C8D1 (n= 2,2,1,1,0,1,3,3,0,0,5,1, 27) | 999999 (± 999999) | 109 (± 99999) | 30.8 (± 30.4) | 86.8 (± 54.4) |
| C9D1(n= 1,2, 1, 1, 0, 2, 3, 3, 0, 0, 5, 2, 22) | 999999 (± 999999) | 124 (± 23.2) | 27.3 (± 27.1) | 94.8 (± 69.4) |
| C10D1(n= 1, 1, 1, 1, 0, 2, 3, 3, 0, 0, 4, 1, 23) | 999999 (± 999999) | 98.3 (± 5.05) | 33.4 (± 34.8) | 84.2 (± 57.4) |

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 3 | 17 | 14 |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1D1(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 66) | 999 (± 999) | 9999 (± 9999) | 9999 (± 9999) | 999 (± 999) |
| C1D2(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 67) | 9999 (± 9999) | 999 (± 999) | 999 (± 999) | 9999 (± 9999) |
| C1D8(n= 3, 4, 3,6,3,6,3,3,1,3,16,14,67) | 125 (± 99999) | 58.0 (± 14.3) | 115 (± 38.0) | 109 (± 58.5) |
| C1D15(n= 3,4,3, 6, 3, 6,3, 3, 1,3 17,14,67) | 329 (± 99999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C1D22(n= 3,4,3,6,3,6,3,3,0,3,17,14,67) | 999999 (± 999999) | 9999 (± 9999) | 9999 (± 9999) | 9999 (± 9999) |
| C2D1(n= 3,3,3,4,3,6,3,3,0,3,12,11,56) | 999999 (± 999999) | 52.4 (± 17.7) | 106 (± 28.8) | 114 (± 40.1) |
| C3D1(n= 2,3,2, 4,2,6,3,3,0,3,11,6,46) | 999999 (± 999999) | 44.7 (± 14.2) | 92.1 (± 30.7) | 93.9 (± 35.6) |
| C4D1(n=2,2,2,4,1,5,3,3,0,3,10,6,43) | 999999 (± 999999) | 48.2 (± 20.8) | 113 (± 70.0) | 102 (± 61.5) |
| C5D1(n= 2,2,0,3,1,3,3,3,0,2,7, 2, 34) | 999999 (± 999999) | 51.6 (± 2.64) | 102 (± 26.3) | 147 (± 105) |
| C6D1 (n= 2,2,1,1,1,3,3,3,0,1,7,2, 35) | 999999 (± 999999) | 45.9 (± 99999) | 100 (± 22.9) | 150 (± 116) |
| C7D1(n= 2,2,1,1,1,3,3,3,0,1 5,1, 28) | 999999 (± 999999) | 45.3 (± 99999) | 108 (± 20.2) | 248 (± 99999) |

| | | | | |
|---|---|---|---|---|
| C8D1 (n= 2,2,1,1,0,1,3,3,0,0,5,1, 27) | 999999 (± 999999) | 999999 (± 999999) | 147 (± 82.2) | 177 (± 99999) |
| C9D1(n= 1,2, 1, 1, 0, 2, 3, 3, 0, 0, 5, 2, 22) | 999999 (± 999999) | 999999 (± 999999) | 95.0 (± 7.59) | 192 (± 25.9) |
| C10D1(n= 1, 1, 1, 1, 0, 2, 3, 3, 0, 0, 4, 1, 23) | 999999 (± 999999) | 999999 (± 999999) | 113 (± 27.6) | 215 (± 99999) |

| **End point values** | Part A-MEDI-551 12 mg/kg (expansion) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 67 | | | |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1D1(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 66) | 2.97 (± 24.1) | | | |
| C1D2(n= 3, 4, 3, 6, 3, 6, 3, 3, 1, 3, 17, 14, 67) | 9999 (± 9999) | | | |
| C1D8(n= 3, 4, 3,6,3,6,3,3,1,3,16,14,67) | 9999 (± 9999) | | | |
| C1D15(n= 3,4,3, 6, 3, 6,3, 3, 1,3 17,14,67) | 9999 (± 9999) | | | |
| C1D22(n= 3,4,3,6,3,6,3,3,0,3,17,14,67) | 9999 (± 9999) | | | |
| C2D1(n= 3,3,3,4,3,6,3,3,0,3,12,11,56) | 124 (± 64.8) | | | |
| C3D1(n= 2,3,2, 4,2,6,3,3,0,3,11,6,46) | 113 (± 70.3) | | | |
| C4D1(n=2,2,2,4,1,5,3,3,0,3,10,6,43) | 113 (± 57.1) | | | |
| C5D1(n= 2,2,0,3,1,3,3,3,0,2,7, 2, 34) | 117 (± 60.9) | | | |
| C6D1 (n= 2,2,1,1,1,3,3,3,0,1,7,2, 35) | 123 (± 67.9) | | | |
| C7D1(n= 2,2,1,1,1,3,3,3,0,1 5,1, 28) | 109 (± 64.2) | | | |
| C8D1 (n= 2,2,1,1,0,1,3,3,0,0,5,1, 27) | 114 (± 63.8) | | | |
| C9D1(n= 1,2, 1, 1, 0, 2, 3, 3, 0, 0, 5, 2, 22) | 121 (± 77.5) | | | |
| C10D1(n= 1, 1, 1, 1, 0, 2, 3, 3, 0, 0, 4, 1, 23) | 139 (± 80.4) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Peak Serum Concentration of MEDI-551 by Treatment Cycle

| End point title | Peak Serum Concentration of MEDI-551 by Treatment Cycle |
|---|---|

End point description:

Peak serum concentration is concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose. The PK population was analysed for this endpoint, which included all participants who received at least one dose of MEDI-551 and had at least one measurable serum concentration of MEDI-551. Here, the arbitrary numbers "999", "9999", and "99999", signifies that no participants were analysed, standard deviation is not reported as only one participant was evaluable, and analysis is not applicable, for the specified arms respectively.

| End point type | Secondary |
|---|---|

End point timeframe:

For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1 D1 (n= 3,4,3,4,3,6,3,3,1,3,17, 13, 62) | 12.3 (± 1.20) | 22.8 (± 1.24) | 46.0 (± 22.2) | 100 (± 11.0) |
| C1D2 (n= 3,4,3,6,3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C1D8 (n= 3,4,3,6,3,6,3,3,1,3,16, 13, 67) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C1D15(n= 3,4 3,6 3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C1D22(n= 3,4,3,6,3,6,3,3 0,3 17, 14, 67) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C2D1(n= 3,3,3,4 3,6 3,3 0,3,12, 10, 53 ) | 27.5 (± 0.752) | 43.9 (± 13.2) | 48.8 (± 21.7) | 149 (± 29.7) |
| C3D1(n= 2,3,2,4,2,6,3,3 0,3,11,6, 46) | 26.3 (± 2.20) | 46.4 (± 16.6) | 58.7 (± 0.783) | 145 (± 31.2) |
| C4D1 (n= 2,2,2,4 1,5 3,3 0,3 10, 6, 41) | 30.3 (± 5.46) | 48.3 (± 12.7) | 63.7 (± 35.1) | 161 (± 85.6) |
| C5D1(n= 2,2 0,2 1,3 3,3 0,2 7,2, 32) | 39.4 (± 6.85) | 70.8 (± 5.43) | 999 (± 999) | 151 (± 58.1) |
| C6D1 (n= 2,2 1,1,1,3, 3, 3, 0, 1, 6, 2, 35 ) | 40.4 (± 3.87) | 34.4 (± 4.21) | 43.2 (± 9999) | 123 (± 9999) |
| C7D1(n= 2,2 1,1, 1, 3,3 3,0,1,5, 1, 27) | 41.3 (± 4.72) | 39.5 (± 30.8) | 41.0 (± 9999) | 123 (± 9999) |
| C8D1 (n= 2,2 1,1 0,1, 3, 3, 0, 0, 5, 1, 26) | 29.9 (± 12.3) | 58.2 (± 16.9) | 32.2 (± 9999) | 130 (± 9999) |
| C9D1 (n= 1,2 1,1 0,2, 3, 3, 0, 0, 5, 2, 22) | 32.2 (± 9999) | 46.8 (± 5.58) | 37.8 (± 9999) | 127 (± 999) |
| C10D1 (n= 1,1,1,1,0,2, 3, 3, 0, 0, 4, 1, 21) | 43.3 (± 9999) | 33.5 (± 9999) | 42.3 (± 9999) | 133 (± 9999) |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 6 | 3 | 3 |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1 D1 (n= 3,4,3,4,3,6,3,3,1,3,17, 13, 62) | 166 (± 59.5) | 280 (± 99.1) | 122 (± 24.2) | 335 (± 79.1) |
| C1D2 (n= 3,4,3,6,3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C1D8 (n= 3,4,3,6,3,6,3,3,1,3,16, 13, 67) | 99999 (± 99999) | 99999 (± 99999) | 162 (± 17.3) | 393 (± 80.8) |
| C1D15(n= 3,4 3,6 3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | 99999 (± 99999) | 182 (± 31.1) | 517 (± 135) |
| C1D22(n= 3,4,3,6,3,6,3,3 0,3 17, 14, 67) | 99999 (± 99999) | 99999 (± 99999) | 208 (± 46.7) | 533 (± 223) |

| | | | | |
|---|---|---|---|---|
| C2D1(n= 3,3,3,4 3,6 3,3 0,3,12, 10, 53 ) | 238 (± 106) | 467 (± 114) | 186 (± 116) | 749 (± 133) |
| C3D1(n= 2,3,2,4,2,6,3,3 0,3,11,6, 46) | 260 (± 89.6) | 374 (± 116) | 155 (± 38.2) | 374 (± 125) |
| C4D1 (n= 2,2,2,4 1,5 3,3 0,3 10, 6, 41) | 201 (± 9999) | 359 (± 115) | 156 (± 81.7) | 384 (± 169) |
| C5D1(n= 2,2 0,2 1,3 3,3 0,2 7,2, 32) | 203 (± 9999) | 372 (± 113) | 153 (± 71.6) | 363 (± 261) |
| C6D1 (n= 2,2 1,1,1,3, 3, 3, 0, 1, 6, 2, 35 ) | 198 (± 9999) | 345 (± 101) | 130 (± 45.7) | 349 (± 140) |
| C7D1(n= 2,2 1,1, 1, 3,3 3,0,1,5, 1, 27) | 182 (± 9999) | 383 (± 54.6) | 174 (± 60.4) | 333 (± 133) |
| C8D1 (n= 2,2 1,1 0,1, 3, 3, 0, 0, 5, 1, 26) | 999 (± 999) | 409 (± 9999) | 164 (± 52.0) | 342 (± 173) |
| C9D1 (n= 1,2 1,1 0,2, 3, 3, 0, 0, 5, 2, 22) | 999 (± 999) | 391 (± 79.6) | 159 (± 64.7) | 299 (± 69.8) |
| C10D1 (n= 1,1,1,1,0,2, 3, 3, 0, 0, 4, 1, 21) | 999 (± 999) | 307 (± 49.8) | 166 (± 64.1) | 316 (± 189) |

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 3 | 17 | 14 |
| Units: µg/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1 D1 (n= 3,4,3,4,3,6,3,3,1,3,17, 13, 62) | 199 (± 9999) | 99999 (± 99999) | 99999 (± 99999) | 260 (± 87.3) |
| C1D2 (n= 3,4,3,6,3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | 160 (± 23.5) | 214 (± 79.9) | 99999 (± 99999) |
| C1D8 (n= 3,4,3,6,3,6,3,3,1,3,16, 13, 67) | 470 (± 9999) | 246 (± 76.1) | 115 (± 38.0) | 303 (± 97.4) |
| C1D15(n= 3,4 3,6 3,6,3,3,1,3 17, 14, 67) | 619 (± 9999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C1D22(n= 3,4,3,6,3,6,3,3 0,3 17, 14, 67) | 999 (± 999) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) |
| C2D1(n= 3,3,3,4 3,6 3,3 0,3,12, 10, 53 ) | 999 (± 999) | 205 (± 33.5) | 304 (± 108) | 333 (± 72.7) |
| C3D1(n= 2,3,2,4,2,6,3,3 0,3,11,6, 46) | 999 (± 999) | 192 (± 78.1) | 311 (± 74.0) | 277 (± 95.7) |
| C4D1 (n= 2,2,2,4 1,5 3,3 0,3 10, 6, 41) | 999 (± 999) | 212 (± 84.1) | 261 (± 99.4) | 295 (± 116) |
| C5D1(n= 2,2 0,2 1,3 3,3 0,2 7,2, 32) | 999 (± 999) | 250 (± 82.3) | 290 (± 66.0) | 338 (± 245) |
| C6D1 (n= 2,2 1,1,1,3, 3, 3, 0, 1, 6, 2, 35 ) | 999 (± 999) | 209 (± 9999) | 332 (± 102) | 303 (± 237) |
| C7D1(n= 2,2 1,1, 1, 3,3 3,0,1,5, 1, 27) | 999 (± 999) | 235 (± 9999) | 392 (± 93.0) | 502 (± 9999) |
| C8D1 (n= 2,2 1,1 0,1, 3, 3, 0, 0, 5, 1, 26) | 999 (± 999) | 999 (± 999) | 317 (± 150) | 511 (± 9999) |
| C9D1 (n= 1,2 1,1 0,2, 3, 3, 0, 0, 5, 2, 22) | 999 (± 999) | 999 (± 999) | 363 (± 90.3) | 593 (± 200) |
| C10D1 (n= 1,1,1,1,0,2, 3, 3, 0, 0, 4, 1, 21) | 999 (± 999) | 999 (± 999) | 349 (± 70.4) | 484 (± 9999) |

| **End point values** | Part A-MEDI-551 12 mg/kg (expansion) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 67 | | | |
| Units: µg/mL | | | | |

| arithmetic mean (standard deviation) | | | | |
|---|---|---|---|---|
| C1 D1 (n= 3,4,3,4,3,6,3,3,1,3,17, 13, 62) | 240 (± 90.0) | | | |
| C1D2 (n= 3,4,3,6,3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | | | |
| C1D8 (n= 3,4,3,6,3,6,3,3,1,3,16, 13, 67) | 99999 (± 99999) | | | |
| C1D15(n= 3,4 3,6 3,6,3,3,1,3 17, 14, 67) | 99999 (± 99999) | | | |
| C1D22(n= 3,4,3,6,3,6,3,3 0,3 17, 14, 67) | 99999 (± 99999) | | | |
| C2D1(n= 3,3,3,4 3,6 3,3 0,3,12, 10, 53 ) | 350 (± 130) | | | |
| C3D1(n= 2,3,2,4,2,6,3,3 0,3,11,6, 46) | 326 (± 110) | | | |
| C4D1 (n= 2,2,2,4 1,5 3,3 0,3 10, 6, 41) | 342 (± 119) | | | |
| C5D1(n= 2,2 0,2 1,3 3,3 0,2 7,2, 32) | 347 (± 98.1) | | | |
| C6D1 (n= 2,2 1,1,1,3, 3, 3, 0, 1, 6, 2, 35 ) | 337 (± 82.1) | | | |
| C7D1(n= 2,2 1,1, 1, 3,3 3,0,1,5, 1, 27) | 355 (± 95.7) | | | |
| C8D1 (n= 2,2 1,1 0,1, 3, 3, 0, 0, 5, 1, 26) | 367 (± 102) | | | |
| C9D1 (n= 1,2 1,1 0,2, 3, 3, 0, 0, 5, 2, 22) | 394 (± 125) | | | |
| C10D1 (n= 1,1,1,1,0,2, 3, 3, 0, 0, 4, 1, 21) | 394 (± 157) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551

| End point title | Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551 |
|---|---|

End point description:

Area under the concentration-time curve at steady state (Css, AUC) of MEDI-551 is reported. Pharmacokinetic (PK) population was analysed for this endpoint, which included all participants who received at least one dose of MEDI-551 and had at least one measurable serum concentration of MEDI-551. Here, the arbitrary number "999" signifies that data not reported due to limited PK data up to Cycle 1 Day 15.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: µgday/mL | | | | |
| arithmetic mean (standard deviation) | 212 (± 28.1) | 287 (± 110) | 479 (± 57.7) | 1660 (± 778) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 6 | 3 | 3 |
| Units: µgday/mL | | | | |
| arithmetic mean (standard deviation) | 2880 (± 2190) | 5720 (± 1620) | 1730 (± 1030) | 4920 (± 1440) |

| End point values | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 3 | 17 | 14 |
| Units: µgday/mL | | | | |
| arithmetic mean (standard deviation) | 999 (± 999) | 2240 (± 338) | 4260 (± 1340) | 4250 (± 2000) |

| End point values | Part A-MEDI-551 12 mg/kg (expansion) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 67 | | | |
| Units: µgday/mL | | | | |
| arithmetic mean (standard deviation) | 4850 (± 1720) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Apparent Clearance of MEDI-551

| End point title | Apparent Clearance of MEDI-551 |
|---|---|

End point description:

Apparent clearance of MEDI-551 is reported. The PK population was analysed for this endpoint, which included all participants who received at least one dose of MEDI-551 and had at least one measurable serum concentration of MEDI-551. Here, the arbitrary number "999" signifies that standard deviation is not reported as only one participant was evaluable for the specified arm.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: mL/day | | | | |
| arithmetic mean (standard deviation) | 206 (± 101) | 302 (± 173) | 373 (± 70.9) | 210 (± 28.9) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 6 | 3 | 3 |
| Units: mL/day | | | | |
| arithmetic mean (standard deviation) | 268 (± 126) | 198 (± 44.3) | 303 (± 108) | 243 (± 81.6) |

| End point values | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 3 | 17 | 14 |
| Units: mL/day | | | | |
| arithmetic mean (standard deviation) | 279 (± 999) | 288 (± 43.0) | 235 (± 87.5) | 237 (± 72.5) |

| End point values | Part A-MEDI-551 12 mg/kg (expansion) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 67 | | | |
| Units: mL/day | | | | |
| arithmetic mean (standard deviation) | 235 (± 110) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Volume of Distribution of MEDI-551

| End point title | Volume of Distribution of MEDI-551 |
|---|---|

End point description:

Volume of distribution was defined as the theoretical volume in which the total amount of drug would

need to be uniformly distributed to produce the desired serum concentration of a drug. Central volume of distribution (Vd1) is defined as hypothetical volume into which a drug initially distributes upon administration and peripheral volume of distribution (Vd2) is defined as the sum of all tissue spaces outside the central compartment. The PK population was analysed for this endpoint, which included all participants who received at least one dose of MEDI-551 and had at least one measurable serum concentration of MEDI-551. Here, the arbitrary number "999" signifies that standard deviation is not reported as only one participant was evaluable for the specified arm.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Vd1 | 3970 (± 851) | 3920 (± 491) | 4350 (± 948) | 4070 (± 464) |
| Vd2 | 2670 (± 351) | 2010 (± 1080) | 1980 (± 888) | 2290 (± 767) |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 6 | 3 | 3 |
| Units: mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Vd1 | 4210 (± 510) | 4230 (± 234) | 3560 (± 286) | 4490 (± 947) |
| Vd2 | 2620 (± 1240) | 2920 (± 1070) | 3290 (± 1440) | 2640 (± 1840) |

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 3 | 17 | 14 |
| Units: mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Vd1 | 5690 (± 999) | 4520 (± 126) | 4350 (± 851) | 4510 (± 647) |
| Vd2 | 3670 (± 999) | 4590 (± 847) | 2640 (± 1200) | 3200 (± 1440) |

| **End point values** | Part A-MEDI-551 12 mg/kg (expansion) | | | |
|---|---|---|---|---|

| Subject group type | Subject analysis set | | | |
|---|---|---|---|---|
| Number of subjects analysed | 67 | | | |
| Units: mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Vd1<br>Vd2 | 4450 (± 889)<br>3430 (± 2250) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Terminal Half-life (t1/2) of MEDI-551

| End point title | Terminal Half-life (t1/2) of MEDI-551 |
|---|---|

End point description:

Terminal half-life is the time required for the plasma concentration of MEDI-551 to fall by 50% during the terminal phase. The PK population was analysed for this endpoint, which included all participants who received at least one dose of MEDI-551 and had at least one measurable serum concentration of MEDI-551. Here, the arbitrary number "999" signifies that standard deviation is not reported as only one participant was evaluable for the specified arm.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

| End point values | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Days | | | | |
| arithmetic mean (standard deviation) | 26.0 (± 6.88) | 17.3 (± 7.65) | 13.3 (± 6.41) | 22.1 (± 3.26) |

| End point values | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 6 | 3 | 3 |
| Units: Days | | | | |
| arithmetic mean (standard deviation) | 21.7 (± 8.65) | 27.9 (± 9.08) | 19.9 (± 9.34) | 23.8 (± 10.9) |

| End point values | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 3 | 17 | 14 |

| | | | | |
|---|---|---|---|---|
| Units: Days | | | | |
| arithmetic mean (standard deviation) | 25.1 (± 999) | 25.3 (± 4.40) | 23.6 (± 9.38) | 25.6 (± 7.96) |

| **End point values** | Part A-MEDI-551 12 mg/kg (expansion) | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 67 | | | |
| Units: Days | | | | |
| arithmetic mean (standard deviation) | 28.9 (± 15.0) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI-551

| End point title | Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI-551[69] |
|---|---|

End point description:

Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI-551 is reported. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551. Participants only with positive ADA is reported.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:C1D1; Part B: C1D1; Part C: C1D1; Part D: C1D1; End of treatment (EOT); 90 Days post last dose (approximately 9 years)

Notes:

[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: Participants | | | | |
| C1D1 | 0 | 1 | 0 | 0 |
| EOT | 0 | 0 | 0 | 0 |
| 90 Day Post Dose0 | 0 | 0 | 0 | 0 |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 76 | 3 | 3 |
| Units: Participants | | | | |

| | | | | |
|---|---|---|---|---|
| C1D1 | 0 | 2 | 0 | 0 |
| EOT | 0 | 0 | 0 | 0 |
| 90 Day Post Dose0 | 0 | 0 | 0 | 0 |

| **End point values** | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 3 | 17 | 14 | |
| Units: Participants | | | | |
| C1D1 | 0 | 0 | 2 | |
| EOT | 0 | 0 | 0 | |
| 90 Day Post Dose0 | 0 | 0 | 0 | |

### Statistical analyses

No statistical analyses for this end point

### Secondary: B-cell Concentration in Serum

| End point title | B-cell Concentration in Serum |
|---|---|

End point description:

B-cell concentration in serum is reported. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551.Safety population included all participants who received any treatment of MEDI-551. It was pre-specified that B-cell analysis was not required, due to limited data availability.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:C1D1 of each cycles; Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10; Part D: C1D1, C1D8, Day 1 of each cycle until Cycle 10; EOT;90 Days post last dose (approximately 9 years)

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0[70] | 0[71] | 0[72] | 0[73] |
| Units: mg/dL | | | | |

Notes:

[70] - It was pre-specified that B-cell analysis was not required, due to limited data availability

[71] - It was pre-specified that B-cell analysis was not required, due to limited data availability

[72] - It was pre-specified that B-cell analysis was not required, due to limited data availability

[73] - It was pre-specified that B-cell analysis was not required, due to limited data availability

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg |
|---|---|---|---|---|

| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
|---|---|---|---|---|
| Number of subjects analysed | 0[74] | 0[75] | 0[76] | 0[77] |
| Units: mg/dL | | | | |

Notes:

[74] - It was pre-specified that B-cell analysis was not required, due to limited data availability
[75] - It was pre-specified that B-cell analysis was not required, due to limited data availability
[76] - It was pre-specified that B-cell analysis was not required, due to limited data availability
[77] - It was pre-specified that B-cell analysis was not required, due to limited data availability

| **End point values** | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + rituximab | Part C-MEDI-551 12 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0[78] | 0[79] | 0[80] | 0[81] |
| Units: mg/dL | | | | |

Notes:

[78] - It was pre-specified that B-cell analysis was not required, due to limited data availability
[79] - It was pre-specified that B-cell analysis was not required, due to limited data availability
[80] - It was pre-specified that B-cell analysis was not required, due to limited data availability
[81] - It was pre-specified that B-cell analysis was not required, due to limited data availability

### Statistical analyses

No statistical analyses for this end point

## Secondary: Immunoglobulin (Ig) Concentration in Serum

| End point title | Immunoglobulin (Ig) Concentration in Serum[82] |
|---|---|

End point description:

Immunoglobin (Ig) concentration in serum is reported. The safety population was analysed for this endpoint, which included all participants who received any treatment of MEDI-551. Here, the arbitrary numbers "9999 and 999"signifies that no participants were analysed for the specified arm and standard deviation is not reported as only one participant was evaluable for the specified arm respectively.

| End point type | Secondary |
|---|---|

End point timeframe:

Part A:C1D1 of each cycles; EOT;90 Days post last dose (approximately 9 years)

Notes:

[82] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

| **End point values** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 3 | 4 | 3 | 6 |
| Units: mg/dL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1D1 (n= 3, 4, 3, 6, 3, 68) | 120.00 (± 46.36) | 110.00 (± 76.25) | 81.00 (± 66.36) | 61.67 (± 54.52) |

| | | | | |
|---|---|---|---|---|
| C2D1 (n= 2, 33, 4, 2, 59) | 67.50 (± 7.78) | 113.67 (± 92.81) | 67.67 (± 58.05) | 57.00 (± 47.05) |
| C3D1 (n= 2, 3, 2, 4, 2, 50) | 62.50 (± 6.36) | 106.00 (± 87.93) | 31.00 (± 29.70) | 57.25 (± 48.29) |
| C4D1 (n= 2, 2, 2, 3, 1, 50) | 64.00 (± 9.90) | 152.50 (± 13.44) | 31.00 (± 33.94) | 63.67 (± 56.52) |
| C5D1 (2, 2, 1, 3, 1, 38) | 69.00 (± 11.31) | 145.50 (± 38.89) | 50.00 (± 999) | 58.67 (± 45.17) |
| C6D1 (2, 2, 0, 1, 1, 36) | 63.50 (± 13.44) | 156.00 (± 48.08) | 9999 (± 9999) | 41.00 (± 999) |
| C7D1 (n= 2, 1, 1, 1, 1, 31) | 56.00 (± 1.41) | 127.00 (± 999) | 47.00 (± 999) | 41.00 (± 999) |
| C8D1 (n= 2, 2, 1, 1, 0, 29) | 47.00 (± 7.07) | 147.00 (± 28.28) | 45.00 (± 999) | 41.00 (± 999) |
| C9D1 (n= 1, 2, 1, 1, 0, 26) | 51.00 (± 999) | 137.50 (± 30.41) | 46.00 (± 999) | 41.00 (± 999) |
| C10D1 (1, 1, 1, 1, 0, 24) | 47.00 (± 999) | 155.00 (± 999) | 46.00 (± 999) | 41.00 (± 999) |
| EOT (n= 2, 3, 3, 5, 3, 48) | 43.50 (± 12.02) | 96.00 (± 80.58) | 7.00 (± 999) | 54.40 (± 46.55) |
| 90 Days Post Dose (n= 1, 2, 0, 3, 0, 15) | 49.00 (± 999) | 84.50 (± 60.10) | 9999 (± 9999) | 93.33 (± 42.06) |

| **End point values** | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 76 | | |
| Units: mg/dL | | | | |
| arithmetic mean (standard deviation) | | | | |
| C1D1 (n= 3, 4, 3, 6, 3, 68) | 93.33 (± 46.11) | 93.01 (± 88.56) | | |
| C2D1 (n= 2, 33, 4, 2, 59) | 74.50 (± 47.38) | 88.90 (± 92.05) | | |
| C3D1 (n= 2, 3, 2, 4, 2, 50) | 76.50 (± 50.20) | 67.90 (± 66.59) | | |
| C4D1 (n= 2, 2, 2, 3, 1, 50) | 98.00 (± 999) | 66.84 (± 61.83) | | |
| C5D1 (2, 2, 1, 3, 1, 38) | 77.00 (± 999) | 69.24 (± 70.45) | | |
| C6D1 (2, 2, 0, 1, 1, 36) | 71.00 (± 999) | 62.86 (± 65.04) | | |
| C7D1 (n= 2, 1, 1, 1, 1, 31) | 61.00 (± 999) | 67.26 (± 69.36) | | |
| C8D1 (n= 2, 2, 1, 1, 0, 29) | 9999 (± 9999) | 73.76 (± 66.87) | | |
| C9D1 (n= 1, 2, 1, 1, 0, 26) | 9999 (± 9999) | 62.35 (± 61.90) | | |
| C10D1 (1, 1, 1, 1, 0, 24) | 9999 (± 9999) | 73.17 (± 66.34) | | |
| EOT (n= 2, 3, 3, 5, 3, 48) | 65.33 (± 19.76) | 217.25 (± 1003.38) | | |
| 90 Days Post Dose (n= 1, 2, 0, 3, 0, 15) | 9999 (± 9999) | 45.20 (± 38.72) | | |

**Statistical analyses**

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Day 1 through 90-Day Post Last Dose (Approximately 9 years)

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 20.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Part A-MEDI-551 0.5 mg/kg |

Reporting group description:

Participants received intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part A-MEDI-551 1 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part A-MEDI-551 4 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part A-MEDI-551 2 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part A-MEDI-551 8 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part B-MEDI-551 6 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part A-MEDI-551 12 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part B-MEDI-551 12 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| | |
|---|---|
| Reporting group title | Part B-MEDI-551 24 mg/kg |

Reporting group description:

Participants received IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation was observed.

| Reporting group title | Part C-MEDI-551 8 mg/kg + rituximab |
|---|---|

Reporting group description:

Participants received IV infusion of 8 mg/kg on days 2 and 8 during Cycle 1 and day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m2 on days 1, 8, 15, and 22. From Cycle 3 only MEDI-551 8 mg/kg was administered on day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws consent.

| Reporting group title | Part D-MEDI-551 12 mg/kg |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment was continued until the participants experiences unacceptable toxicity, disease progression, reached CR or consent withdrawal.

| Reporting group title | Part C-MEDI-551 12 mg/kg + rituximab |
|---|---|

Reporting group description:

Participants received IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg was administered on Day 1 of each 28-day cycle. The treatment was continued until the participants experienced unacceptable toxicity, disease progression, reached complete response or withdraws consent.

| **Serious adverse events** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| number of deaths (all causes) | 0 | 2 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diffuse large b-cell lymphoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polycythaemia vera | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock haemorrhagic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Pulmonary haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cauda equina syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxic encephalopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Faecaloma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |

| | | | |
|---|---|---|---|
| Acute hepatic failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pemphigoid | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteolysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Sepsis syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varicella | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Part A-MEDI-551 2 | Part A-MEDI-551 8 | Part B-MEDI-551 6 |
|---|---|---|---|

| | mg/kg | mg/kg | mg/kg |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 1 / 3 (33.33%) | 1 / 3 (33.33%) |
| number of deaths (all causes) | 2 | 2 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diffuse large b-cell lymphoma | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polycythaemia vera | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock haemorrhagic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary haemorrhage | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cauda equina syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxic encephalopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Blood and lymphatic system disorders** | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| **Gastrointestinal disorders** | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Faecaloma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Acute hepatic failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pemphigoid | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteolysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varicella | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 23 / 76 (30.26%) | 2 / 3 (66.67%) | 1 / 1 (100.00%) |
| number of deaths (all causes) | 30 | 0 | 1 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diffuse large b-cell lymphoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Malignant melanoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Polycythaemia vera | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock haemorrhagic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Pulmonary haemorrhage | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 6 / 6 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Spinal compression fracture | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cauda equina syndrome | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxic encephalopathy | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Faecaloma | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |

| | | | |
|---|---|---|---|
| Acute hepatic failure | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pemphigoid | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteolysis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 3 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Sepsis syndrome | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Varicella | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Part C-MEDI-551 8 | Part D-MEDI-551 12 | Part C-MEDI-551 12 |
|---|---|---|---|

| | mg/kg + rituximab | mg/kg | mg/kg + rituximab |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 5 / 14 (35.71%) | 9 / 17 (52.94%) |
| number of deaths (all causes) | 2 | 8 | 9 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diffuse large b-cell lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-hodgkin's lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Polycythaemia vera | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock haemorrhagic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |

| | | | |
|---|---|---|---|
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cauda equina syndrome | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxic encephalopathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Faecaloma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Acute hepatic failure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pemphigoid | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteolysis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Sepsis syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varicella | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 2 %

| **Non-serious adverse events** | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 4 mg/kg |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 4 / 4 (100.00%) | 6 / 6 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bowen's disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemangioma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Metastatic lymphoma | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 3 / 4 (75.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |

| | | | |
|---|---|---|---|
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Phlebitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Systolic hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Breakthrough pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Cyst | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 2 / 6 (33.33%) |
| occurrences (all) | 1 | 5 | 2 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gravitational oedema | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ill-defined disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infusion site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mass | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site bruise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Necrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 1 | 1 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 6 (33.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Hypogammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Immune system disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Social circumstances | | | |
| Ex-tobacco user | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|---|---|---|---|
| Breast swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematospermia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nipple disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Dry throat | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 1 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Increased bronchial secretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasal polyps | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Obstructive airways disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Paranasal sinus hypersecretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary alveolar haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sneezing | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sputum discoloured | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat tightness | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Aggression | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Agitation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Depressed mood | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Hallucinations, mixed | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood albumin decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood chloride decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood fibrinogen decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood fibrinogen increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood immunoglobulin m decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood phosphorus decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Electrocardiogram qt prolonged | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose urine present | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematocrit decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Karnofsky scale worsened | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Low density lipoprotein increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Mean cell volume increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neutrophil count abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 2 | 5 | 4 |
| Occult blood positive | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Serum ferritin decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin d decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Fall | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 6 (33.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Laceration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural complication | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access complication | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wrong drug administered | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atrial tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bradycardia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anosmia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cerebrovascular accident | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypersomnia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypergammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Polycythaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenomegaly | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 3 / 6 (50.00%) |
| occurrences (all) | 0 | 1 | 7 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoacusis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otorrhoea | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Exophthalmos | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal incontinence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 5 | 0 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 10 | 4 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Impaired gastric emptying | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Salivary hypersecretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Tongue coated | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 1 | 1 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Eczema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 2 |
| Erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema annulare | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperhidrosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ingrowing nail | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Macule | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Petechiae | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purpura | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash erythematous | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin exfoliation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Solar lentigo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobinuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine flow decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bursitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Groin pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 1 | 1 |
| Inguinal mass | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spondylitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bacterial vaginosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Ear infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 2 / 6 (33.33%) |
| occurrences (all) | 0 | 0 | 3 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pustular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 2 | 1 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 6 | 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | 1 / 6 (16.67%) |
| occurrences (all) | 0 | 6 | 2 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin d deficiency | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 4 (0.00%) | 0 / 6 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| **Non-serious adverse events** | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 8 mg/kg | Part B-MEDI-551 6 mg/kg |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 3 / 3 (100.00%) | 3 / 3 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bowen's disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Haemangioma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metastatic lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Squamous cell carcinoma of skin | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Phlebitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systolic hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Breakthrough pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cyst | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 3 / 3 (100.00%) | 2 / 3 (66.67%) |
| occurrences (all) | 1 | 3 | 2 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gravitational oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ill-defined disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mass | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site bruise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Necrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Hypogammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Immune system disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Social circumstances | | | |
| Ex-tobacco user | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Breast swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematospermia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nipple disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal | | | |

| | | | |
|---|---|---|---|
| disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry throat | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Increased bronchial secretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal polyps | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Obstructive airways disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Paranasal sinus hypersecretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Pleural effusion | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary alveolar haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Sneezing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sputum discoloured | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat tightness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Wheezing | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Aggression | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Agitation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depressed mood | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucinations, mixed | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood albumin decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood chloride decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood fibrinogen decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood fibrinogen increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood immunoglobulin m decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood phosphorus decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Electrocardiogram qt prolonged | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose urine present | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematocrit decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Karnofsky scale worsened | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Low density lipoprotein increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mean cell volume increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Occult blood positive | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Serum ferritin decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin d decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 6 |
| Laceration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Post-traumatic pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural complication | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access complication | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wrong drug administered | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atrial tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Cardiac failure chronic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anosmia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypersomnia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Seizure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tremor | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypergammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Polycythaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenomegaly | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Deafness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoacusis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Otorrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Exophthalmos | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal incontinence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|---|---|---|
| Dental caries | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 0 | 1 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Salivary hypersecretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tongue coated | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blister | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema annulare | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ingrowing nail | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Macule | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Petechiae | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Purpura | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash erythematous | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin exfoliation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Solar lentigo | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemoglobinuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Urine flow decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bursitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Groin pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Inguinal mass | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 3 (33.33%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Muscular weakness | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spondylitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Bacterial vaginosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 2 / 3 (66.67%) |
| occurrences (all) | 1 | 0 | 2 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 1 | 0 | 1 |

| | | | |
|---|---|---|---|
| Laryngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 2 / 3 (66.67%) |
| occurrences (all) | 1 | 0 | 3 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pustular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 6 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 2 / 3 (66.67%) |
| occurrences (all) | 0 | 0 | 6 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin d deficiency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| **Non-serious adverse events** | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 75 / 76 (98.68%) | 3 / 3 (100.00%) | 1 / 1 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bowen's disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Haemangioma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metastatic lymphoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Flushing | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Haematoma | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |

| | | | |
|---|---|---|---|
| Hot flush | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 8 / 76 (10.53%) | 2 / 3 (66.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 8 | 5 | 0 |
| Hypotension | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 3 | 0 | 1 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Phlebitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systolic hypertension | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 5 / 76 (6.58%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 6 | 0 | 0 |
| Breakthrough pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 5 / 76 (6.58%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 6 | 4 | 0 |
| Cyst | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Early satiety | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 28 / 76 (36.84%) | 3 / 3 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 33 | 6 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gravitational oedema | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ill-defined disorder | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Infusion site pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Malaise | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Mass | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Medical device site bruise | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Medical device site pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Necrosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 8 / 76 (10.53%) | 2 / 3 (66.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 9 | 5 | 2 |
| Pain | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 5 / 76 (6.58%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 9 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 13 / 76 (17.11%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 18 | 4 | 0 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Hypogammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorder | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Social circumstances | | | |
| Ex-tobacco user | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Breast swelling | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematospermia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nipple disorder | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 26 / 76 (34.21%) | 3 / 3 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 31 | 7 | 0 |
| Dry throat | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 9 / 76 (11.84%) | 2 / 3 (66.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 10 | 6 | 1 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Epistaxis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Increased bronchial secretion | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Nasal polyps | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Obstructive airways disorder | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 2 / 3 (66.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 4 | 0 |
| Paranasal sinus hypersecretion | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Pulmonary alveolar haemorrhage | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pulmonary hypertension | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Sinus congestion | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sputum discoloured | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Throat tightness | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 6 | 0 |
| Psychiatric disorders | | | |
| Aggression | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Agitation | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 8 / 76 (10.53%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 8 | 1 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|---|---|---|---|
| Depressed mood | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hallucinations, mixed | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 8 / 76 (10.53%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 8 | 0 | 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 3 | 0 | 2 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 4 | 0 | 3 |
| Blood albumin decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 1 | 0 | 2 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood chloride decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 1 | 1 | 1 |
| Blood fibrinogen decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood fibrinogen increased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Blood immunoglobulin m decreased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 3 | 0 | 1 |
| Blood phosphorus decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Blood potassium decreased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 5 | 0 |
| Electrocardiogram qt prolonged | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Glucose urine present | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematocrit decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Karnofsky scale worsened | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Low density lipoprotein increased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 11 |
| Mean cell volume increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count abnormal | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 5 / 76 (6.58%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 7 | 3 | 1 |
| Occult blood positive | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 3 | 1 | 1 |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Serum ferritin decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vitamin d decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| White blood cell count decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 3 / 76 (3.95%) | 2 / 3 (66.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 4 | 4 | 8 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 0 | 1 |
| Fall | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Infusion related reaction | | | |
| subjects affected / exposed | 34 / 76 (44.74%) | 2 / 3 (66.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 108 | 8 | 1 |
| Laceration | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural complication | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular access complication | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wrong drug administered | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 2 | 0 |
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Atrial tachycardia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 7 | 0 | 0 |

| | | | |
|---|---|---|---|
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Anosmia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Dizziness | | | |
| subjects affected / exposed | 10 / 76 (13.16%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 12 | 0 | 1 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 15 / 76 (19.74%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 20 | 7 | 0 |
| Hypersomnia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Paraesthesia | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Peripheral sensory neuropathy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus headache | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 8 | 1 | 2 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypergammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 5 | 0 |
| Lymph node pain | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Lymphopenia | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 13 / 76 (17.11%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 19 | 13 | 0 |
| Polycythaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Splenomegaly | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Ear swelling | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoacusis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Otorrhoea | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Exophthalmos | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 0 | 1 |

| | | | |
|---|---|---|---|
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 4 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Anal incontinence | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 10 / 76 (13.16%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 12 | 3 | 0 |
| Dental caries | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 18 / 76 (23.68%) | 2 / 3 (66.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 21 | 3 | 2 |
| Dry mouth | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 3 | 0 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Dysphagia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 2 / 3 (66.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 13 / 76 (17.11%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 16 | 1 | 0 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Salivary hypersecretion | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Tongue coated | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 7 / 76 (9.21%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 8 | 1 | 0 |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Blister | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ecchymosis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eczema | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Erythema | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Erythema annulare | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 5 / 76 (6.58%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Ingrowing nail | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Macule | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 7 | 1 | 0 |
| Petechiae | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 7 / 76 (9.21%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 11 | 1 | 0 |
| Purpura | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 11 / 76 (14.47%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 19 | 1 | 0 |
| Rash erythematous | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scab | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin exfoliation | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Solar lentigo | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Dysuria | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Haemoglobinuria | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urine flow decreased | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 2 / 3 (66.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 9 | 5 | 0 |
| Arthritis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Back pain | | | |
| subjects affected / exposed | 11 / 76 (14.47%) | 2 / 3 (66.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 12 | 4 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Bursitis | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Groin pain | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Inguinal mass | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 9 / 76 (11.84%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 11 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 0 | 1 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 2 | 1 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Myalgia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 4 / 76 (5.26%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 6 / 76 (7.89%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 9 | 2 | 0 |
| Pain in jaw | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Spondylitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Bacterial vaginosis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 2 / 3 (66.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 6 | 3 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---|---|---|
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 5 | 2 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Pneumonia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash pustular | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 9 / 76 (11.84%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 11 | 10 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 8 / 76 (10.53%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 9 | 1 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 7 / 76 (9.21%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 7 | 1 | 1 |
| Dehydration | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 3 / 76 (3.95%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 7 | 0 | 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 4 / 76 (5.26%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 2 / 76 (2.63%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 4 | 0 | 2 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 1 / 3 (33.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 1 | 2 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 76 (1.32%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hypomagnesaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 76 (2.63%) | 1 / 3 (33.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin d deficiency | | | |
| subjects affected / exposed | 0 / 76 (0.00%) | 0 / 3 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| **Non-serious adverse events** | Part C-MEDI-551 8 mg/kg + rituximab | Part D-MEDI-551 12 mg/kg | Part C-MEDI-551 12 mg/kg + rituximab |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 14 / 14 (100.00%) | 17 / 17 (100.00%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Benign neoplasm of thyroid gland | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Bowen's disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemangioma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metastatic lymphoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seborrhoeic keratosis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Skin papilloma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Flushing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 2 | 4 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 1 | 2 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Phlebitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Systolic hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 4 |
| Breakthrough pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Chills | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 3 | 1 |
| Cyst | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Early satiety | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 5 / 14 (35.71%) | 9 / 17 (52.94%) |
| occurrences (all) | 2 | 6 | 20 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 3 / 17 (17.65%) |
| occurrences (all) | 0 | 1 | 3 |
| Gravitational oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Ill-defined disorder | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mass | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Medical device site bruise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Medical device site pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Necrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oedema peripheral | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 5 / 17 (29.41%) |
| occurrences (all) | 0 | 2 | 9 |
| Pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Performance status decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 2 | 3 |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Immune system disorders | | | |
| Hypogammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Immune system disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Social circumstances | | | |
| Ex-tobacco user | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Reproductive system and breast disorders | | | |
| Breast swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Erectile dysfunction | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematospermia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nipple disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 3 / 17 (17.65%) |
| occurrences (all) | 0 | 5 | 3 |
| Dry throat | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 4 / 17 (23.53%) |
| occurrences (all) | 0 | 1 | 5 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 2 |
| Increased bronchial secretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasal congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 3 |
| Nasal polyps | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Obstructive airways disorder | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paranasal sinus hypersecretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 5 |
| Pulmonary alveolar haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Sneezing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sputum discoloured | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Throat tightness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 2 | 4 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Psychiatric disorders | | | |
| Aggression | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Agitation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Anxiety | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 1 | 1 | 4 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 2 | 2 |
| Depressed mood | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Depression | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 14 (7.14%) | 3 / 17 (17.65%) |
| occurrences (all) | 1 | 1 | 3 |
| Hallucination | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Hallucinations, mixed | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|---|---|---|
| Insomnia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 4 / 14 (28.57%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 4 | 5 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Sleep disorder | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Product issues | | | |
| Device dislocation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood albumin decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 1 | 4 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood chloride decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood cholesterol increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Blood fibrinogen decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood fibrinogen increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood immunoglobulin m decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood iron decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Blood phosphorus decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Blood triglycerides increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| C-reactive protein increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Electrocardiogram qt prolonged | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glucose urine present | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematocrit decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Karnofsky scale worsened | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Low density lipoprotein increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 3 / 14 (21.43%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 3 | 7 |
| Mean cell volume increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count abnormal | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 4 / 14 (28.57%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 4 | 2 |
| Occult blood positive | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet count decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Prostatic specific antigen increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Protein total decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Serum ferritin decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin d decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 5 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 3 / 14 (21.43%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 4 | 4 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Fall | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Infusion related reaction | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 4 / 14 (28.57%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 12 | 1 |
| Laceration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Post-traumatic pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural complication | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Vascular access complication | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Wrong drug administered | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Atrial flutter | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atrial tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 2 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 2 |
| Nervous system disorders | | | |
| Amnesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anosmia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 3 / 14 (21.43%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 4 | 2 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Headache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 3 / 17 (17.65%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypersomnia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Memory impairment | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 1 | 0 | 1 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Seizure | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Sinus headache | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 4 / 17 (23.53%) |
| occurrences (all) | 0 | 3 | 18 |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypergammaglobulinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Lymphopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Neutropenia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 1 | 2 | 7 |
| Polycythaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Splenomegaly | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 4 | 19 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Deafness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Ear swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoacusis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Otorrhoea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vertigo | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry eye | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Exophthalmos | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 1 | 3 |
| Abdominal pain lower | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal incontinence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Constipation | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 2 / 14 (14.29%) | 6 / 17 (35.29%) |
| occurrences (all) | 1 | 2 | 7 |
| Dental caries | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 3 / 14 (21.43%) | 5 / 17 (29.41%) |
| occurrences (all) | 1 | 4 | 15 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 2 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 3 | 2 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Inguinal hernia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip dry | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Nausea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 3 / 14 (21.43%) | 5 / 17 (29.41%) |
| occurrences (all) | 2 | 3 | 9 |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Salivary hypersecretion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Tongue coated | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Toothache | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 4 / 17 (23.53%) |
| occurrences (all) | 1 | 0 | 6 |
| Hepatobiliary disorders | | | |

| | | | |
|---|---|---|---|
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| **Skin and subcutaneous tissue disorders** | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Blister | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Ecchymosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eczema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Erythema annulare | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ingrowing nail | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Macule | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Petechiae | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Purpura | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 3 / 17 (17.65%) |
| occurrences (all) | 0 | 0 | 4 |
| Rash erythematous | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Scab | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin exfoliation | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin irritation | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Solar lentigo | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Bladder spasm | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Haemoglobinuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |

| | | | |
|---|---|---|---|
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 1 | 1 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Urine flow decreased | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 3 / 17 (17.65%) |
| occurrences (all) | 1 | 0 | 6 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 2 / 3 (66.67%) | 2 / 14 (14.29%) | 4 / 17 (23.53%) |
| occurrences (all) | 2 | 6 | 5 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Bursitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Groin pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inguinal mass | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 3 | 1 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 2 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 2 | 5 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 5 / 17 (29.41%) |
| occurrences (all) | 0 | 0 | 6 |
| Pain in jaw | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sarcopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Spondylitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bacterial vaginosis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 3 | 1 |
| Candida infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Chronic sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 14 (7.14%) | 1 / 17 (5.88%) |
| occurrences (all) | 1 | 1 | 7 |

| | | | |
|---|---|---|---|
| Furuncle | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Influenza | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 4 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 2 | 2 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash pustular | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Rhinitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 4 / 17 (23.53%) |
| occurrences (all) | 0 | 2 | 8 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 3 / 17 (17.65%) |
| occurrences (all) | 0 | 2 | 4 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 5 / 14 (35.71%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 6 | 2 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 2 | 4 |
| Hyperkalaemia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 0 / 17 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 2 | 1 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 6 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 14 (7.14%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 1 | 2 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 14 (14.29%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 2 | 5 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 5 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 6 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 2 / 17 (11.76%) |
| occurrences (all) | 0 | 0 | 3 |
| Vitamin d deficiency | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 0 / 14 (0.00%) | 1 / 17 (5.88%) |
| occurrences (all) | 0 | 0 | 1 |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 28 May 2009 | Inclusion criterion number 11 amended. Exclusion criterion 1 added to exclude participants who were eligible for a life-prolonging or life-saving standard line of therapy. |
| 06 November 2009 | Text was added to indicate that an interim safety analysis was to be conducted when the MTD or OBD had been established. Inclusion criterion number 3 was edited to specify that the chronic lymphocytic leukemia (CLL) population was to include participants with SLL. Inclusion criterion number 10 was edited to specify platelet count >= 75,000/mm^3 (except for CLL participants with evidence of bone marrow disease, who must have had a platelet count >= 50,000/mm^3. Inclusion criterion number 12 was edited to clarify the recommended methods of contraception and to state that participants must use adequate contraception methods through 90 days after the last dose of MEDI-551. Inclusion criterion number 13 was edited to specify that for participants with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) only, disease was to be evaluable by the International Working Group criteria (formerly RECIST criteria). An additional analysis population, the Per-protocol population (defined as all participants who completed 2 cycles of treatment or who discontinued treatment for toxicity due to MEDI-551, disease progression, or death due to disease) was added. |
| 27 January 2010 | Exclusion criterion number 12 was edited to clarify that participants with active hepatitis B or C infection as defined by seropositivity for hepatitis are not eligible to participate in the study. |
| 23 September 2010 | The study design and treatment sections of the protocol were updated to specify that dose escalation began in participants with FL or multiple myeloma (MM) per Protocol Version 4.0 through Cohort 2, and that Cohorts 3 to 6 would enroll participants with FL, MM, CLL or DLBCL with a modified dosing schedule. Participants in Cohorts 1 and 2 would continue to follow the Protocol Version 4.0 dose schedule of 0.5 mg/kg (Cohort 1) or 1 mg/kg (Cohort 2) MEDI-551 IV infusion QW in 4-week cycles. Participants enrolled on Cohorts 3 and higher were to receive 2, 4, 8, or 12 mg/kg MEDI-551 (Cohorts 3 to 6, respectively) IV once per week on Days 1 and 8 in the first cycle (loading doses) and then Q4W at the start of each subsequent cycle on Days 1 and 8 in the first cycle (loading doses) and then Q4W at the start of each subsequent cycle. |
| 18 July 2011 | The text was updated to specify that all participants (US and non-US) who achieved a CR may receive an additional 2 cycles of MEDI-551 at the same dose level. The FDA were to be consulted concerning the possibility of additional treatment with MEDI-551 for participants within the US who achieved a CR and subsequently relapse; however, non-US participants were not to be re-treated on subsequent relapse. The objective response rate was revised from 12 weeks to 8 weeks. |
| 04 October 2011 | Sections throughout the protocol were amended to state that the maximum dose-escalation phase dose of 12 mg/kg was selected for the expansion phase of the study. An additional safety follow-up visit at 60 days after the last dose was added (subsequent Protocol Versions increased doses of MEDI-551 above 12 mg/kg). |

| | |
|---|---|
| 02 May 2012 | Sections throughout the protocol were modified to note discontinuation of enrollment of MM participants. The expansion phase was to enrol approximately 60 participants: 20 participants each with FL, CLL (including small lymphocytic lymphoma [SLL]), or DLBCL. All eligibility criteria and evaluations pertaining to participants with MM were removed. Inclusion criterion number 3 was modified to state that participants with a diagnosis of CLL (including SLL), DLBCL, or FL are included and that SLL, DLBCL, and FL must be histologically confirmed. Inclusion criterion number 7 was revised to specify that permitted prior radiation therapy must have occurred at least 6 weeks before the first dose of MEDI-551. Inclusion criteria number 10 was changed to provide different hematological criteria for CLL participants with BM involvement. Inclusion criterion number 11 was changed to modify the definition of adequate organ function. IgE testing was removed. |
| 15 July 2013 | Text was added to specify that study completion would be after the deaths of 50% of all planned participants or the date the sponsor stops the study. Inclusion criterion number 5 had the term SLL removed. |
| 07 October 2013 | Primary, secondary, and exploratory objectives and endpoints were added for Arms B and C. Inclusion criteria numbers 3 to 6, and 10 were revised to reflect the participants to be included in Arms B and C. Exclusion criterion number 10 was modified to indicate that it only applied to Arm A. A sentence was added to indicate that the schedule of study procedures for Arms A, B, and C are presented in separate subsections. The schedule of study procedures and by-visit descriptions of procedures were added for Arm B and Arm C. The Per-protocol population was removed, and the statistical analysis for efficacy, safety and sample size were all updated to include the assessments for Arms A, B and C. |
| 21 March 2014 | Primary, secondary, and exploratory objectives and endpoints were added for Arm D. Inclusion criteria numbers 3, 5, 6 and 10 were revised. Inclusion criterion number 4 was revised indicating fresh tumor biopsy was optional and applicable to Arm D. Exclusion criteria numbers 4 and 5 were revised to reflect a washout period of 28 days or 5 half-lives instead of 6 weeks. Exclusion criteria number 7 was revised indicating “live or attenuated” vaccines. Exclusion criterion number 9 was removed. Exclusion criteria numbers 18 and 20 were revised for clarification. Schedule of study procedures and by-visit descriptions of procedures were added for Arm D. In addition, schedule of study procedures and by-visit descriptions of procedures for Arms B and C were updated to include Karnofsky performance status assessment and BM biopsy with minimal residual disease analysis. Statistical analysis for efficacy, safety and sample size were all updated to include assessments for Arm D. |
| 27 January 2015 | Language was added where relevant to describe the dosing schedule for participnats in Arm B receiving 24 or 48 mg/kg dose levels of MEDI-551. The initial doses were to be administered over 2 days on Day 1 and Day 2 in Cycle 1. Exclusion criterion number 12 was modified. Exclusion criterion number 22 was added. |
| 01 June 2017 | Key safety assessments relevant to MEDI-551 were retained. Vital signs were to be evaluated pre-dose and at end of infusion only. Exploratory evaluations were removed. Disease evaluations were to be performed at regular intervals to determine whether MEDI-551 was continuing to provide clinical benefit. Study completion was updated to be defined as the date of the last protocol-specified visit for the last participants in the study. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported